var title_f34_23_35184="Conjugated equine estrogens: Drug information";
var content_f34_23_35184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Conjugated equine estrogens: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12624513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12624514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/51/28472?source=see_link\">",
"       Conjugated equine estrogens (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19399?source=see_link\">",
"       Conjugated equine estrogens (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9424 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35184=[""].join("\n");
var outline_f34_23_35184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/51/28472?source=related_link\">",
"      Conjugated equine estrogens (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/60/19399?source=related_link\">",
"      Conjugated equine estrogens (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_23_35185="Patient information: Granuloma annulare (The Basics)";
var content_f34_23_35185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87301\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/7/32883\">",
"         Granuloma annulare on the hand",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/9/20624\">",
"          Granuloma annulare on the foot",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/51/14130\">",
"           Granuloma annulare on the leg",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/57/37778\">",
"         Patient information: Steroid medicines (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Granuloma annulare (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H589342599\">",
"      <span class=\"h1\">",
"       What is granuloma annulare?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Granuloma annulare is a skin condition that can cause a red, raised, circle-shaped rash. There are 2 main types of granuloma annulare:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Localized &ndash; The rash affects only 1 part of the body. This type of granuloma annulare is much more common.",
"       </li>",
"       <li>",
"        Generalized &ndash; The rash affects more than 1 part of the body. This type of granuloma annulare is less common.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      This condition can last for a while. Most of the time, the localized type of granuloma annulare goes away by itself within 2 years.",
"     </p>",
"     <p>",
"      Granuloma annulare can happen in children and adults. Doctors don&rsquo;t know what causes it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H589342614\">",
"      <span class=\"h1\">",
"       What are the symptoms of granuloma annulare?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms depend on the type of granuloma annulare.",
"     </p>",
"     <p>",
"      Localized granuloma annulare most commonly causes 1 or more circle-shaped areas of red, raised skin that are not scaly. The center of the area is usually skin-colored (",
"      <a class=\"graphic graphic_picture graphicRef87100 \" href=\"UTD.htm?32/7/32883\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef87101 \" href=\"UTD.htm?20/9/20624\">",
"       picture 2",
"      </a>",
"      ). Localized granuloma annulare usually affects the wrists, ankles, backs of the hands, and tops of the feet. It is not usually itchy.",
"     </p>",
"     <p>",
"      Generalized granuloma annulare can cause different types of rashes and skin symptoms. Most commonly, it causes many red, raised, circle- or arc-shaped areas on different parts of the body (",
"      <a class=\"graphic graphic_picture graphicRef87099 \" href=\"UTD.htm?13/51/14130\">",
"       picture 3",
"      </a>",
"      ). This rash is sometimes itchy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H589342629\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not always. Your doctor or nurse might be able to tell if you have this condition by doing an exam and looking at your rash.",
"     </p>",
"     <p>",
"      If your doctor or nurse is not sure whether you have granuloma annulare, he or she might scrape your skin and look at the scrapings under a microscope. This test helps tell whether you have an infection that can look like granuloma annulare.",
"     </p>",
"     <p>",
"      Some people have a test called a skin biopsy. For this test, a doctor takes a small sample of skin from the rash. Then another doctor looks at it under a microscope.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H589342644\">",
"      <span class=\"h1\">",
"       How is granuloma annulare treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the type of granuloma annulare you have and how bothersome your symptoms are.",
"     </p>",
"     <p>",
"      If your rash is not itchy or bothersome, you probably do not need treatment. Your rash will most likely go away by itself over time.",
"     </p>",
"     <p>",
"      If your symptoms bother you, there are different treatments that might help.",
"     </p>",
"     <p>",
"      Treatment for localized granuloma annulare can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Steroid ointments or creams that go on the rash &ndash; These steroids are different from the ones athletes take to build muscle. These medicines help reduce inflammation and itching.",
"       </li>",
"       <li>",
"        Shots of steroid medicines that go into the rash",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatment for generalized granuloma annulare can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Steroid ointments or creams that go on the rash",
"       </li>",
"       <li>",
"        Light therapy &ndash; For this treatment, your doctor will use a machine that gives off a special type of light.",
"       </li>",
"       <li>",
"        Steroid pills",
"       </li>",
"       <li>",
"        Other types of medicines",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H589342659\">",
"      <span class=\"h1\">",
"       Will my rash return?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In some cases, the rash returns after treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H589342674\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=see_link\">",
"       Patient information: Steroid medicines (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?34/23/35185?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87301 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35185=[""].join("\n");
var outline_f34_23_35185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589342599\">",
"      What is granuloma annulare?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589342614\">",
"      What are the symptoms of granuloma annulare?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589342629\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589342644\">",
"      How is granuloma annulare treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589342659\">",
"      Will my rash return?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589342674\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87301\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/7/32883\">",
"      Granuloma annulare on the hand",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/9/20624\">",
"       Granuloma annulare on the foot",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/51/14130\">",
"        Granuloma annulare on the leg",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=related_link\">",
"      Patient information: Steroid medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_23_35186="Bronchogenic carcinoma CT V";
var content_f34_23_35186=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Advanced bronchogenic carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Bronchogenic carcinoma with a right-sided drowned lung. CT scan of the lower chest shows a large, opacified right lung with mucoid bronchograms appearing as low attenuation branching structures. Right panel: Upper abdominal CT scan shows several large low attenuation metastases in the liver, which define an M1b lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35186=[""].join("\n");
var outline_f34_23_35186=null;
var title_f34_23_35187="Perflutren protein type A: Drug information";
var content_f34_23_35187=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Perflutren protein type A: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/22/38243?source=see_link\">",
"    see \"Perflutren protein type A: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3033664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Optison&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3033667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3034064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Opacification of left ventricle:",
"     </b>",
"     I.V.:  0.5 mL via peripheral vein; flush with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS following dose; may repeat in increments of 0.5 mL up to 5 mL cumulatively in 10 minutes (maximum total dose: 8.7 mL in any one patient study)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3034065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3034070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Optison&trade;: Perflutren 0.11-0.33 mg and protein-type A microspheres 5-8 x 10",
"     <sup>",
"      8",
"     </sup>",
"     per mL (3 mL) [contains human albumin 10 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3033665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3034066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     While allowing the vial to come to room temperature, invert and gently rotate to resuspend the microspheres; solution should appear milky-white. Do",
"     <b>",
"      not",
"     </b>",
"     use if solution is clear. Vent vial with a sterile vent spike or 18-gauge needle. Do",
"     <b>",
"      not",
"     </b>",
"     inject air into vial. Within 1 minute of resuspension, remove dose from the vial and inject into a peripheral vein at a rate &le;1 mL/second. Flush line with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS immediately after injection. Repeat resuspension prior to injection if more than 1 minute elapses.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3033668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Opacification of left ventricular chamber and improvement of delineation of the left ventricular endocardial border in patients with suboptimal echocardiograms",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3033678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (4%), chest pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5%), dizziness (3%), chills/fever (1%), malaise/weakness/fatigue (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (4%), altered taste (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site discomfort (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reaction, angioedema, arthralgia, atrial fibrillation, back pain, body or muscle aches, bradycardia, bronchospasm, burning sensation in the eyes, cardiac arrest, cardiopulmonary reaction, cough, discoloration at the injection site, edema (pharyngeal, palatal, mouth, peripheral, localized), eosinophilia, erythema, eye irritation, hypersensitivity, hypertension, hypoesthesia, hypotension, hypoxia, induration, irritability, loss of consciousness, oxygen desaturation (due to coughing), palpitation, paresthesia, photophobia, premature ventricular contraction, pruritus, rash, respiratory arrest, respiratory distress, seizure, shock, stridor, supraventricular fibrillation, supraventricular tachycardia, swelling (face, eye, lip, tongue, upper airway), syncope, tachycardia, tinnitus, tremor, urticaria, ventricular fibrillation, ventricular tachycardia, visual blurring, wheezing, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3033673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to perflutren or any component of the formulation, blood, blood products, or albumin; right-to-left, bidirectional, or transient right-to-left cardiac shunt; administration by intra-arterial injection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3033674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Boxed warning:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serious cardiopulmonary reactions: See &ldquo;Concerns related to adverse effects&rdquo; below",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Postmarketing reports of anaphylactoid reactions (eg, shock, hypersensitivity, bronchospasm, throat tightness, angioedema, edema [oropharyngeal, peripheral, and localized], swelling [face, eye, lip, tongue, upper airway], facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema) have been reported in patients with no prior exposure. Monitor for signs and symptoms of anaphylactoid reactions. Immediate treatment (including epinephrine 1:1000) should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serious cardiopulmonary reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Serious cardiopulmonary reactions (some fatal) have occurred uncommonly during or within 30 minutes following administration. Ensure patient does not have any contraindications for use. Equipment for resuscitation and trained personnel experienced in handling medical emergencies should always be immediately available.",
"     </b>",
"     Risk may be increased in patients with unstable cardiopulmonary conditions (eg, acute MI, acute coronary syndromes, worsening or unstable HF, serious ventricular arrhythmias).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation: Transient QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (&gt;30 msec) has been observed with another microbubble contrast agent (perflutren lipid microsphere), some with associated cardiac rhythm changes; malignant symptomatology was not observed in clinical trials. Clinical trials evaluating the effects of perflutren protein-type A microspheres on the QT interval have not been conducted; however, effects on the QT interval are expected to be similar. Monitor patients at high risk of arrhythmias due to QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ventricular arrhythmias: High ultrasound mechanical indices with or without end-systolic triggering may cause ventricular arrhythmias. Safety of perflutren protein-type A microspheres with mechanical indices &gt;0.8 or end-systolic triggering has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac shunts: Patients with right-to-left, bidirectional, or transient right-to-left cardiac shunts should",
"     <b>",
"      not",
"     </b>",
"     receive perflutren protein-type A microspheres. Use of phospholipid encapsulated microspheres will result in microvascular occlusion and ischemia since the pulmonary particle-filtering mechanism will be bypassed resulting in a direct transfer from venous to arterial circulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Congenital heart defects: Extreme caution should be used in patients with congenital heart defects. Safety and efficacy have not been established in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Product contains albumin; may carry a remote risk of virus transmission or hypersensitivity reaction.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3033669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3033670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxic, fetotoxic, and teratogenic effects were observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use only when potential benefits outweigh the potential hazards to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3033672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3034069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for cardiopulmonary reactions in all patients; in high-risk patients (ie, unstable cardiopulmonary conditions), closely monitor blood pressure, heart rate, oxygen saturation, cardiac rhythm (during and for 30 minutes following infusion)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3033996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perflutren is a stable gas that provides an echogenic contrast effect in the blood and allows for improved delineation of the left ventricular endocardial border.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3033998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Contrast enhancement: Dose dependent: 1 minute (0.2 mL) to 5 minutes (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Perflutren: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 0.6-2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Perflutren: Lungs",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10335 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35187=[""].join("\n");
var outline_f34_23_35187=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709205\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033664\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033667\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3034064\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3034065\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3034070\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033665\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3034066\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033668\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033678\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033673\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033674\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299853\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222246\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033669\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033670\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033672\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3034069\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033996\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033998\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10335\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10335|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/22/38243?source=related_link\">",
"      Perflutren protein type A: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_23_35188="Metabolic emergencies at birth";
var content_f34_23_35188=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metabolic emergencies at birth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35188/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35188/contributors\">",
"     Jochen Profit, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35188/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35188/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35188/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35188/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/23/35188/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic emergencies that commonly present at or soon after birth are hypoglycemia, hypocalcemia, hypermagnesemia, and metabolic acidosis. Inborn errors of metabolism also can become apparent shortly after birth, although most present after 1 to 2 days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35188/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of common metabolic emergencies that occur at birth is presented here. Inborn errors of metabolism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HYPOGLYCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;With loss of the continuous infusion of glucose through the placenta, plasma glucose concentration in the healthy term newborn falls during the first two hours after birth, reaching a nadir rarely below 40",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and then stabilizes by 4 to 6 hours of age in the range of 45 to 80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35188/abstract/2\">",
"     2",
"    </a>",
"    ]. Glucose concentration is maintained immediately after birth by the breakdown of hepatic glycogen (glycogenolysis) in response to epinephrine and glucagon and is facilitated by falling insulin levels.",
"   </p>",
"   <p>",
"    Neonatal hypoglycemia including pathogenesis, clinical manifestations, evaluation and treatment are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HYPOCALCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early hypocalcemia typically occurs in the first two to three days after birth and rarely is seen in the first few hours following delivery. It occurs commonly in premature infants, and infants of diabetic mothers (IDMs), and those with perinatal asphyxia and intrauterine growth restriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=see_link\">",
"     \"Neonatal hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors contribute to the fall in total serum calcium (Ca) in premature infants and include hypoalbuminemia, which does not lower the ionized Ca, and factors that lower both total and ionized Ca such as reduced intake of Ca because of low intake of milk, possible impaired response to parathyroid hormone (PTH), increased calcitonin levels, and increased urinary losses accompanying high renal sodium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35188/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Hypocalcemia in IDMs is thought to be caused by lower PTH concentrations after birth compared to those of normal infants [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35188/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of hypocalcemia depends upon gestational age and birth weight:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In term infants or premature infants greater than 1500 g birth weight, we define hypocalcemia as a total serum Ca concentration of less than 8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or an ionized fraction of less than 4.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.1",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Premature infants with birth weight less than 1500 g are considered to have hypocalcemia if they have a total serum Ca concentration of less than 7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.75",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      <strong>",
"       In general, symptoms are uncommon in infants &lt; 1500 g whose ionized calcium is &gt; 0.8",
"       <span class=\"nowrap\">",
"        mmol/L.",
"       </span>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infants with hypocalcemia are asymptomatic. Among those who become symptomatic, the characteristic sign is increased neuromuscular irritability. Such infants are jittery and often have muscle jerking that is induced by environmental noise or other stimuli. Generalized or focal clonic seizures can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because most infants are asymptomatic, we monitor serum Ca concentration for infants at risk for hypocalcemia (ie, infants who are premature, or with perinatal asphyxia or intrauterine growth restrictions) with measurement of an ionized Ca at 24 and 48 hours of age and as clinically indicated thereafter. Ionized Ca is optimal because only this measurement is used to assess the risk of symptoms. Total serum Ca is measured if ionized Ca is unavailable. Serum Ca also is measured in any infant with signs consistent with hypocalcemia and in infants with congenital heart disease. Management of infants with hypocalcemia is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=see_link\">",
"     \"Neonatal hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HYPERMAGNESEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypermagnesemia that occurs soon after birth typically results from maternal treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    for preeclampsia or tocolysis. Serum magnesium concentration greater than 2.3",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (1.15",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    is considered abnormal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link\">",
"     \"Inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected infants are depressed and have generalized hypotonia. In severe cases, respiratory depression with apnea may occur. Hypermagnesemia also may result in decreased gastrointestinal motility and meconium plug syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35188/abstract/7\">",
"     7",
"    </a>",
"    ]. The severity of signs and symptoms does not appear to be directly related to the magnesium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Evaluation and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal hypermagnesemia from maternal treatment is typically self-limited, and we do not routinely follow serum magnesium concentrations. If renal function is normal, magnesium levels usually normalize within several days, and symptoms resolve. Infants should be observed for signs of feeding intolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     METABOLIC ACIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic acidosis occurring immediately after birth typically is caused by elevated lactate levels resulting from perinatal hypoxemia and ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35188/abstract/8\">",
"     8",
"    </a>",
"    ]. The increased lactate concentration results in an elevated anion gap (&gt;15",
"    <span class=\"nowrap\">",
"     mEq/L).",
"    </span>",
"   </p>",
"   <p>",
"    An",
"    arterial blood sample to detect metabolic acidosis should be obtained in an infant with perinatal depression. Treatment consists of prompt resuscitative measures with restoration of oxygenation and circulation. The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    has not been shown to improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35188/abstract/9\">",
"     9",
"    </a>",
"    ]. However, in the absence of a response of the patient to other resuscitative measures, we administer intravenous sodium bicarbonate at a dose of 2",
"    <span class=\"nowrap\">",
"     mEq/kg",
"    </span>",
"    (4",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 0.5",
"    <span class=\"nowrap\">",
"     mEq/mL",
"    </span>",
"    solution). If buffer therapy is necessary beyond the immediate resuscitation, we prefer providing it as a continuous infusion of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/55/883?source=see_link\">",
"     sodium acetate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Infants with inborn errors of metabolism, such as organic acidemias, may present with metabolic acidosis and increased anion gap soon after birth, generally after feeding. These disorders are less common than is perinatal depression. A family history or associated clinical findings such as dysmorphic features, severe hypotonia, seizures, or apnea, may be diagnostic clues [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35188/abstract/1,10,11\">",
"     1,10,11",
"    </a>",
"    ]. Presentation and evaluation of these disorders are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common metabolic emergencies that present at or soon after birth include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoglycemia &mdash; At birth, because of the loss of the continuous infusion of glucose through the placenta, the blood glucose normally decreases to a nadir (rarely below 40",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      at two hours, which stabilizes by four to six hours of age in term infants. Hypoglycemia, defined as glucose below 40",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      results from diminished glucose production or increased utilization. The former is caused primarily by inadequate glycogen stores associated with prematurity or intrauterine growth restriction, and the latter typically is caused by hyperinsulinism, most commonly occurring in infants of diabetic mothers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hypoglycemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link\">",
"       \"Neonatal hypoglycemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypocalcemia &mdash; Early hypocalcemia typically occurs in the first two to three days after birth and rarely is seen in the first few hours following delivery. It occurs commonly in infants who are premature, or with perinatal asphyxia or intrauterine growth restriction. Because most infants are asymptomatic, calcium levels are obtained in these infants who are at risk for neonatal hypocalcemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Hypocalcemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=see_link\">",
"       \"Neonatal hypocalcemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypermagnesemia &mdash; Neonatal hypermagnesemia (serum magnesium &gt;2.3",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      [1.15",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      at birth typically results from maternal treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      for preeclampsia or tocolysis. It is generally self-limited and resolves without intervention. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hypermagnesemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metabolic acidosis &mdash; Metabolic acidosis occurring immediately after birth is due to lactic acidosis from perinatal hypoxemia and ischemia. Treatment is directed towards restoration of oxygenation and circulation. Infants with inborn errors of metabolism may present with metabolic acidosis, such as organic acidemia, but generally do so after feeding. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Metabolic acidosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35188/abstract/1\">",
"      Leonard JV, Morris AA. Inborn errors of metabolism around time of birth. Lancet 2000; 356:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35188/abstract/2\">",
"      Srinivasan G, Pildes RS, Cattamanchi G, et al. Plasma glucose values in normal neonates: a new look. J Pediatr 1986; 109:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35188/abstract/3\">",
"      Schedewie HK, Odell WD, Fisher DA, et al. Parathormone and perinatal calcium homeostasis. Pediatr Res 1979; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35188/abstract/4\">",
"      Tsang RC, Kleinman LI, Sutherland JM, Light IJ. Hypocalcemia in infants of diabetic mothers. Studies in calcium, phosphorus, and magnesium metabolism and parathormone responsiveness. J Pediatr 1972; 80:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35188/abstract/5\">",
"      Venkataraman PS, Tsang RC, Chen IW, Sperling MA. Pathogenesis of early neonatal hypocalcemia: studies of serum calcitonin, gastrin, and plasma glucagon. J Pediatr 1987; 110:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35188/abstract/6\">",
"      Tsang RC, Chen I, Friedman MA, et al. Parathyroid function in infants of diabetic mothers. J Pediatr 1975; 86:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35188/abstract/7\">",
"      Sokal MM, Koenigsberger MR, Rose JS, et al. Neonatal hypermagnesemia and the meconium-plug syndrome. N Engl J Med 1972; 286:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35188/abstract/8\">",
"      Lorenz JM, Kleinman LI, Markarian K, et al. Serum anion gap in the differential diagnosis of metabolic acidosis in critically ill newborns. J Pediatr 1999; 135:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35188/abstract/9\">",
"      Beveridge CJ, Wilkinson AR. Sodium bicarbonate infusion during resuscitation of infants at birth. Cochrane Database Syst Rev 2006; :CD004864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35188/abstract/10\">",
"      Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics 1998; 102:E69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35188/abstract/11\">",
"      Burlina AB, Bonaf&eacute; L, Zacchello F. Clinical and biochemical approach to the neonate with a suspected inborn error of amino acid and organic acid metabolism. Semin Perinatol 1999; 23:162.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5064 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35188=[""].join("\n");
var outline_f34_23_35188=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HYPOGLYCEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HYPOCALCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HYPERMAGNESEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      METABOLIC ACIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=related_link\">",
"      Inborn errors of metabolism: Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=related_link\">",
"      Neonatal hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_23_35189="Bromocriptine: Patient drug information";
var content_f34_23_35189=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bromocriptine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     see \"Bromocriptine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/42/4775?source=see_link\">",
"     see \"Bromocriptine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cycloset&reg;;",
"     </li>",
"     <li>",
"      Parlodel&reg;;",
"     </li>",
"     <li>",
"      Parlodel&reg; SnapTabs&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Bromocriptine;",
"     </li>",
"     <li>",
"      PMS-Bromocriptine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat acromegaly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691842",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat women who do not have a monthly period cycle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691843",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat women who have too much milk.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some prolactin-secreting tumors.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701651",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bromocriptine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2957679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cycloset:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2957959",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have fainting headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2957680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Parlodel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Heart disease, high blood pressure, or poor blood flow to the legs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2957679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cycloset:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Strong urges that are hard to control (such as gambling or sex).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2957679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cycloset:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2957961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take within 2 hours of waking up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11434 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35189=[""].join("\n");
var outline_f34_23_35189=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142570\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142571\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011653\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011655\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011654\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011659\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011660\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011662\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011657\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011658\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011663\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011664\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=related_link\">",
"      Bromocriptine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/42/4775?source=related_link\">",
"      Bromocriptine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_23_35190="Calculation of the creatinine clearance";
var content_f34_23_35190=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Calculation of the creatinine clearance",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35190/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35190/contributors\">",
"     Lesley A Inker, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35190/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35190/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35190/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35190/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35190/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/23/35190/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The creatinine clearance is a widely used test to estimate the glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Creatinine is derived from the metabolism of creatine in skeletal muscle and from dietary meat; it is released into the circulation at a relatively constant rate and has a stable plasma concentration. Like inulin, creatinine is freely filtered across the glomerulus and is neither reabsorbed nor metabolized by the kidney. However, tubular secretion by the organic cation secretory pathways in the proximal tubule accounts for approximately 10 to 20 percent of urinary creatinine in patients with a normal GFR and a progressively higher percentage as the GFR falls [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/3\">",
"     3",
"    </a>",
"    ]. The net effect is progressive overestimation of the GFR with more severe disease. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Increased creatinine secretion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the effect of secretion is ignored, then all of the filtered creatinine (equal to the product of the GFR and the serum creatinine concentration [SCr]) will be excreted (equal to product of the urine creatinine concentration [UCr] and the urine flow rate or volume [V]). Thus:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp;GFR x SCr &nbsp;= &nbsp;UCr x V",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp;GFR = [UCr x",
"    <span class=\"nowrap\">",
"     V]/SCr",
"    </span>",
"   </p>",
"   <p>",
"    This formula is called the creatinine clearance and tends to exceed the true GFR by 10 to 20 percent or more depending upon the proportion of urinary creatinine that is derived from tubular secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/4\">",
"     4",
"    </a>",
"    ]. Historically, this error was balanced by an error of almost equal magnitude in the measurement of the serum creatinine. The error in serum creatinine measurement was due to non-creatinine chromogens (such as acetone, ascorbic acid, and pyruvate) that are present in serum and contributed 10 to 20 percent of the creatinine concentration measured by older colorimetric techniques. However, national standardization of serum creatinine assays to creatinine reference materials has largely abolished this error. If a laboratory is using standardized methods, creatinine clearance measurements will consistently be 10 to 20 percent higher than GFR in patients with a normal GFR and progressive higher as the GFR falls. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Increased creatinine secretion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The creatinine clearance is usually determined from a",
"    <strong>",
"     24-hour",
"    </strong>",
"    urine collection, since shorter collections tend to give less accurate results. One problem with shorter timed collections is that any retained urine would represent a larger percent of the total urine collection. In addition, creatinine excretion varies throughout the day [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16405048\">",
"    <span class=\"h2\">",
"     Example",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppose that the following 24-hour urine results are obtained in a 60 kg woman:",
"   </p>",
"   <p>",
"    &nbsp;SCr &nbsp; &nbsp;= &nbsp; 1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (106",
"    <span class=\"nowrap\">",
"     micromol/L)",
"     <br/>",
"    </span>",
"    &nbsp;UCr &nbsp; &nbsp;= &nbsp; 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8800",
"    <span class=\"nowrap\">",
"     micromol/L)",
"     <br/>",
"    </span>",
"    &nbsp;V &nbsp; &nbsp; &nbsp; = &nbsp; 1.2",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"   </p>",
"   <p>",
"    Thus:",
"   </p>",
"   <p>",
"    &nbsp;CCr &nbsp; = &nbsp;[100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    x 1.2",
"    <span class=\"nowrap\">",
"     L/day]",
"    </span>",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    = 100",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"   </p>",
"   <p>",
"    To convert this value into units of",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    it has to be multiplied by 1000 to convert into mL and then divided by 1440 (the number of minutes in a day):",
"   </p>",
"   <p>",
"    &nbsp;CCr &nbsp; = &nbsp;[100",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    x 1000",
"    <span class=\"nowrap\">",
"     ml/L]",
"    </span>",
"    <span class=\"nowrap\">",
"     /1440",
"    </span>",
"    <span class=\"nowrap\">",
"     min/day",
"    </span>",
"    = 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"   </p>",
"   <p>",
"    A creatinine clearance calculator is provided (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?16/8/16513?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), and the results should ideally be normalized to a body surface area (BSA) of 1.73 m2; BSA can be computed using a different calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?4/27/4529?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As an example, a creatinine clearance of 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in a small woman with a weight and height of 50 kg and 160 cm, who has a BSA of 1.5",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    is normalized to a BSA of 1.73 m2 as follows:",
"   </p>",
"   <p>",
"    CCr x",
"    <span class=\"nowrap\">",
"     1.73/BSA",
"    </span>",
"    = [70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    x 1.73]",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    1.5 = 80",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2",
"   </p>",
"   <p>",
"    For a large person with a body surface area of 1.9",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    the adjusted CCr would be 64",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2.",
"   </p>",
"   <p>",
"    The normal value for the creatinine clearance is 95 &plusmn; 20",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 in women and 120 &plusmn; 25",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 in men [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, a level of 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in a woman suggests the loss of approximately 25 percent of her GFR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIMITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major errors that can limit the accuracy of the creatinine clearance as an estimate of GFR: errors in urine collection; increases in both creatinine secretion and extrarenal creatinine degradation as the GFR falls [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Because of these limitations and because a stable serum creatinine concentration usually reflects stable kidney function, many clinicians estimate the GFR from the serum creatinine concentration using derived estimation equations rather than a timed urine collection. The estimation equations are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Errors in urine collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;An incomplete urine collection will lead to an underestimate of creatinine excretion and therefore of the GFR, while an overcollection (more than 24 hours) will lead to an overestimate of creatinine excretion and therefore of the GFR. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The completeness of the collection can be estimated from knowledge of the normal rate of creatinine excretion, which is equal to creatinine production in the steady state. In adults under the age of 50, daily creatinine excretion should be 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (177 to 221",
"    <span class=\"nowrap\">",
"     micromol/kg)",
"    </span>",
"    lean body weight in men and 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (133 to 177",
"    <span class=\"nowrap\">",
"     micromol/kg)",
"    </span>",
"    lean body weight in women [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/7\">",
"     7",
"    </a>",
"    ]. From the ages of 50 to 90, there is a progressive 50 percent decline in creatinine excretion (to about 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in men), due primarily to a fall in muscle mass. The above patient, for example, excreted 1200 mg (10,600 micromol) of creatinine or 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/kg),",
"    </span>",
"    suggesting that the collection is probably complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16405081\">",
"    <span class=\"h3\">",
"     Example",
"    </span>",
"    &nbsp;&mdash;&nbsp;The creatinine clearance is calculated on two separate occasions in a patient with known renal disease and a stable weight and diet. Despite identical serum creatinine concentrations, the results from the second collection suggest that the creatinine clearance has declined by 20",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    However, this interpretation contrasts with the stability of the patient&rsquo;s weight (muscle mass), diet, and serum creatinine. Based upon the formula for creatinine clearance derived above [UCr x",
"    <span class=\"nowrap\">",
"     V/SCr],",
"    </span>",
"    the difference in creatinine clearance must be related to differences in creatinine excretion (UCr x V). There are two possible explanations: the reduced creatinine excretion in the second specimen reflects either an incomplete second collection or an overcollection in the first specimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Increased creatinine secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even with an accurate urine collection, the accuracy of the creatinine clearance as a measurement of GFR is limited by the fact that, at a normal GFR, 10 to 20 percent of creatinine excretion is derived from secretion in the proximal tubule, resulting in the creatinine clearance being 10 to 20 percent higher than the GFR. As the GFR falls, the associated reductions in creatinine filtration and excretion will result in an increase in serum creatinine, which provides the signal for enhanced creatinine secretion. The increase in secretion counterbalances the reduction in creatinine filtration so that a steady state is reestablished in which creatinine excretion is maintained at the same level as creatinine production with a slightly higher creatinine concentration than before [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/2,4,8-10\">",
"     2,4,8-10",
"    </a>",
"    ]. However, the increase in creatinine secretion will result in the creatinine clearance being a progressively greater overestimate of the GFR.",
"   </p>",
"   <p>",
"    As an example, as the true GFR falls from 80 to 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (as measured by the clearance of an accurate filtration marker such as inulin or radioisotopic iothalamate or DTPA) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/9,11\">",
"     9,11",
"    </a>",
"    ], the absolute amount of secreted creatinine can rise by more than 50 percent, accounting for as much as 35 percent of urinary creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/2\">",
"     2",
"    </a>",
"    ]. In this setting, creatinine excretion is much greater than creatinine filtration. As a result, calculation of the creatinine clearance from a 24-hour urine collection will represent a large overestimate of the true GFR. The net effect is that the creatinine clearance may be normal (&gt;90",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    in about one-half of patients with a true GFR of 61 to 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and one-quarter of those with a true GFR of 51 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/8\">",
"     8",
"    </a>",
"    ]. Some patients with advanced disease have a creatinine clearance that exceeds the GFR by more than twofold.",
"   </p>",
"   <p>",
"    As a result, all that can be concluded is that the creatinine clearance determined from an accurately timed, preferably 24-hour urine collection represents an upper limit of what the true GFR may be. As an example, a creatinine clearance of 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    indicates decreased kidney function, although the GFR may be as low as 35",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Furthermore, the degree of creatinine secretion appears to vary with time, changing the creatinine clearance independent of alterations in the GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In some cases, the change in creatinine clearance is discordant from that of the GFR (as measured by inulin or radioisotopic clearance). Thus, the creatinine clearance can fall modestly (suggesting disease progression) at a time when the GFR is actually increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/10,12\">",
"     10,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More accurate determination of the GFR requires measurement of an exogenous substance such as inulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    , iothalamate, DTPA, or EDTA&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. Inulin is the ideal filtration marker in that it is neither secreted nor reabsorbed, but inulin has not been approved for clinical use in the United States, and is expensive and difficult to handle. The other markers provide reasonable approximations of inulin clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16405108\">",
"    <span class=\"h2\">",
"     Increased extrarenal creatinine degradation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with advanced renal failure (serum creatinine greater than 6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [530",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    extrarenal creatinine degradation is increased due, at least in part to increases in intestinal bacterial overgrowth and bacterial creatininase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/14\">",
"     14",
"    </a>",
"    ]. As a result, the serum creatinine concentration is lower than would be expected from the GFR. This will falsely elevate the creatinine clearance, adding to the problem of increased creatinine secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16405127\">",
"    <span class=\"h2\">",
"     Enhancing the creatinine clearance measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the more accurate inulin or iothalamate clearance is not routinely available. There are two alternatives that may provide a more accurate estimate of the GFR from a timed, preferably 24-hour urine collection in patients with a stable serum creatinine concentration: averaging the creatinine and urea clearances; and measurement of the creatinine clearance during the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    A more commonly used approach in patients with a stable serum creatinine is to estimate the GFR from empirically derived estimation equations. The estimation equations are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45280530\">",
"    <span class=\"h3\">",
"     Averaged creatinine and urea clearances",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative in patients with moderate to advanced renal disease (serum creatinine &gt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [220",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    is to take the average of the creatinine and urea clearances [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/11,15,16\">",
"     11,15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;CCr &nbsp;+ &nbsp;CUrea",
"   </p>",
"   <p>",
"    &nbsp;GFR &nbsp; &nbsp;= &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2",
"   </p>",
"   <p>",
"    The rationale for this formula is that clearance of creatinine overestimates the GFR due to creatinine secretion, whereas the clearance of urea underestimates the GFR since approximately 40 to 50 percent of the filtered urea is reabsorbed. Fortuitously, the two errors tend to be of similar magnitude in patients with moderate to advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Use of cimetidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     Cimetidine",
"    </a>",
"    , an organic cation like creatinine, can competitively diminish proximal tubule creatinine secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/4,17,18\">",
"     4,17,18",
"    </a>",
"    ]. In one study of 16 patients with underlying renal insufficiency, 400 mg of cimetidine was given as an oral priming dose followed by 200 mg every three hours; both the creatinine and inulin clearances were measured every three hours [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/4\">",
"     4",
"    </a>",
"    ]. The ratio of the creatinine to inulin clearance at baseline was about 1.5 (range 1.14 to 2.27), indicating substantial creatinine secretion. The ratio fell to a mean of 1.02 in eight patients, but remained elevated (mean 1.33) in the remaining eight patients who had persistent urinary creatinine secretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41875?source=see_link\">",
"     \"Drugs that elevate the serum creatinine concentration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    have been used in an effort to more reliably lower the creatinine clearance to the true GFR. These intensive cimetidine regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single 1200 mg oral dose with a urine collection obtained between the third and sixth hours and the serum creatinine concentration measured at the beginning and the end of the test [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A loading dose of 1200 to 2000 mg (depending upon renal function) followed by 400 to 800 mg at regular intervals for 3 to 4 days [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/17\">",
"       17",
"      </a>",
"      ]. On the test day, a 1.5 hour urine collection (three 30 min clearance periods) for creatinine clearance was performed, which was as accurate as the more cumbersome 24-hour collection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety of high single doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    has not been established in a large number of patients; it has been suggested that a maximum single dose of 800 mg may be preferable in patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Techniques using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    to reduce creatinine secretion followed by urine collections of less than 24-hours require pretest water loading (up to 10",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    to assure a high urine flow rate and therefore accurate urine collections. Despite these various techniques designed to maximize blockade of creatinine secretion, there will remain intra- and inter-individual variability in the effect of cimetidine on blockade of creatinine secretion, which complicates the interpretation of a cimetidine creatinine clearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16405156\">",
"    <span class=\"h2\">",
"     Inability to detect mild kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephron loss leads to compensatory hypertrophy and hyperfiltration in the normal or less affected nephrons. Because of this adaptive response, the GFR falls very little in mild kidney disease, and measurement of the creatinine clearance or use of an estimation equation will fail to detect the presence of disease. Mild kidney disease may be detectable by abnormal findings in the urinalysis, such as hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link&amp;anchor=H3#H3\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Intraglomerular hypertension and glomerular hypertrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal transplant donors who acutely lose half of their functioning nephrons represent a good example of this phenomenon. Despite the loss of nephrons, the GFR is approximately 70 percent of baseline at 10 to 14 days after donation and 75 to 85 percent of baseline at long-term follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30697?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of the living kidney donor and risk of donor nephrectomy\", section on 'Long-term risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, in patients who begin with a normal GFR, mild to moderate percentage reductions in GFR produce only a small elevation in serum creatinine that may remain within the normal range and within the range of laboratory variability. As an example, a 10 to 15 percent fall in GFR will produce at most a 10 to 15 percent increase in serum creatinine. If, for example, the baseline serum creatinine is 0.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (71",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    the serum creatinine will only increase to 0.9 to 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (80 to 88",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    These relationships have been demonstrated in a variety of disorders, including lupus nephritis and autosomal dominant polycystic kidney disease. In lupus nephritis, progressive glomerulosclerosis and nephron drop-out can occur during the healing phase with little reduction in GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/12,19\">",
"     12,19",
"    </a>",
"    ]. Similarly, in autosomal dominant polycystic kidney disease, the GFR remains stable for many years despite structural distortion due to expansion of kidney cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35190/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, patients with kidney disease must also be monitored for other signs of disease progression, such as an increase in protein excretion or systemic blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H7#H7\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Kidney size'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The creatinine clearance is a widely used test to estimate the glomerular filtration rate (GFR).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Creatinine is derived from the metabolism of creatine in skeletal muscle and from dietary meat; it is released into the circulation at a relatively constant rate and has a stable serum concentration. Like inulin, creatinine is freely filtered across the glomerulus and is neither reabsorbed nor metabolized by the kidney. However, approximately 10 to 20 percent of urinary creatinine is derived from tubular secretion when the GFR is normal and progressively higher as the GFR falls and the serum creatinine rises. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a laboratory is using standardized methods for measuring the serum creatinine, then creatinine clearance measurements will be 10 to 20 percent higher than the GFR if the GFR is normal. The difference will be greater as the GFR falls and creatinine secretion increases. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The creatinine clearance is usually determined from a 24-hour urine collection, since shorter collections tend to give less accurate results. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The creatinine clearance is calculated by dividing the 24-hour urine creatinine by the serum creatinine; the 24-hour urine creatinine is equal to the urine creatinine concentration multiplied by urine volume (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?16/8/16513?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). The creatinine clearance should ideally be normalized to body surface area of 1.73 m2 (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?4/27/4529?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16405048\">",
"       'Example'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several limitations to measurement of the creatinine clearance. Thus, for many patients, ascertaining whether the GFR is changing or is stable can usually be determined by monitoring the serum creatinine concentration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Limitations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An incomplete urine collection leads to an underestimate of creatinine excretion and therefore of the GFR. The completeness of the collection can be estimated from knowledge of the normal rate of creatinine excretion. In adults under the age of 50, daily creatinine excretion should be 20 to 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (177 to 221",
"      <span class=\"nowrap\">",
"       micromol/kg)",
"      </span>",
"      lean body weight in men and 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (133 to 177",
"      <span class=\"nowrap\">",
"       &micro;mol/kg)",
"      </span>",
"      lean body weight in women. After age 50, creatinine excretion falls progressively due to a decrease in muscle mass, and may be as low as 10",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Errors in urine collection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The accuracy of the creatinine clearance is limited by the fact that as the GFR falls, the rise in the serum creatinine is partially ameliorated by enhanced creatinine secretion. As a result, all that can be concluded is that the creatinine clearance, assuming a complete 24-hour urine collection, represents an upper limit of the true GFR. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Increased creatinine secretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two enhancements to the creatinine clearance measurement may provide a more accurate estimate of the GFR: measurement of the creatinine clearance during the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      ; and averaging the creatinine and urea clearances in patients with a moderate to advanced decrease in kidney function. (See",
"      <a class=\"local\" href=\"#H16405127\">",
"       'Enhancing the creatinine clearance measurement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001, pp. 50-57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/2\">",
"      DOOLAN PD, ALPEN EL, THEIL GB. A clinical appraisal of the plasma concentration and endogenous clearance of creatinine. Am J Med 1962; 32:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/3\">",
"      Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/4\">",
"      van Acker BA, Koomen GC, Koopman MG, et al. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 1992; 340:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/5\">",
"      Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/6\">",
"      Payne RB. Creatinine clearance: a redundant clinical investigation. Ann Clin Biochem 1986; 23 ( Pt 3):243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/7\">",
"      Walser M. Creatinine excretion as a measure of protein nutrition in adults of varying age. JPEN J Parenter Enteral Nutr 1987; 11:73S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/8\">",
"      Kim KE, Onesti G, Ramirez O, et al. Creatinine clearance in renal disease. A reappraisal. Br Med J 1969; 4:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/9\">",
"      Levey AS. Measurement of renal function in chronic renal disease. Kidney Int 1990; 38:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/10\">",
"      Petri M, Bockenstedt L, Colman J, et al. Serial assessment of glomerular filtration rate in lupus nephropathy. Kidney Int 1988; 34:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/11\">",
"      Perrone RD, Steinman TI, Beck GJ, et al. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 1990; 16:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/12\">",
"      Myers BD, Chagnac A, Golbetz H, et al. Extent of glomerular injury in active and resolving lupus nephritis: a theoretical analysis. Am J Physiol 1991; 260:F717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/13\">",
"      Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009; 20:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/14\">",
"      Dunn SR, Gabuzda GM, Superdock KR, et al. Induction of creatininase activity in chronic renal failure: timing of creatinine degradation and effect of antibiotics. Am J Kidney Dis 1997; 29:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/15\">",
"      Lubowitz H, Slatopolsky E, Shankel S, et al. Glomerular filtration rate. Determination in patients with chronic renal disease. JAMA 1967; 199:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/16\">",
"      Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/17\">",
"      Hilbrands LB, Artz MA, Wetzels JF, Koene RA. Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int 1991; 40:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/18\">",
"      Zaltzman JS, Whiteside C, Cattran DC, et al. Accurate measurement of impaired glomerular filtration using single-dose oral cimetidine. Am J Kidney Dis 1996; 27:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/19\">",
"      Chagnac A, Kiberd BA, Fari&ntilde;as MC, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989; 84:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35190/abstract/20\">",
"      Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354:2122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2378 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35190=[""].join("\n");
var outline_f34_23_35190=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16405048\">",
"      Example",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Errors in urine collection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16405081\">",
"      - Example",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Increased creatinine secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16405108\">",
"      Increased extrarenal creatinine degradation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16405127\">",
"      Enhancing the creatinine clearance measurement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45280530\">",
"      - Averaged creatinine and urea clearances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Use of cimetidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16405156\">",
"      Inability to detect mild kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?16/8/16513?source=related_link\" title=\"calculator 1\">",
"      Calculator: Creatinine clearance (measured)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?4/27/4529?source=related_link\" title=\"calculator 2\">",
"      Calculator: Body Surface Area (Mosteller, square root method)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41875?source=related_link\">",
"      Drugs that elevate the serum creatinine concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30697?source=related_link\">",
"      Evaluation of the living kidney donor and risk of donor nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_23_35191="Gabapentin: Pediatric drug information";
var content_f34_23_35191=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gabapentin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"    see \"Gabapentin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/8/2182?source=see_link\">",
"    see \"Gabapentin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gralise&trade;;",
"     </li>",
"     <li>",
"      Neurontin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F175024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Gabapentin&reg;;",
"     </li>",
"     <li>",
"      Auro-Gabapentin;",
"     </li>",
"     <li>",
"      CO Gabapentin;",
"     </li>",
"     <li>",
"      Dom-Gabapentin;",
"     </li>",
"     <li>",
"      GD-Gabapentin;",
"     </li>",
"     <li>",
"      JAMP-Gabapentin;",
"     </li>",
"     <li>",
"      Mylan-Gabapentin;",
"     </li>",
"     <li>",
"      Neurontin&reg;;",
"     </li>",
"     <li>",
"      PHL-Gabapentin;",
"     </li>",
"     <li>",
"      PMS-Gabapentin;",
"     </li>",
"     <li>",
"      PRO-Gabapentin;",
"     </li>",
"     <li>",
"      RAN&trade;-Gabapentin;",
"     </li>",
"     <li>",
"      ratio-Gabapentin;",
"     </li>",
"     <li>",
"      Riva-Gabapentin;",
"     </li>",
"     <li>",
"      Teva-Gabapentin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"      see \"Gabapentin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Do not exceed 12 hours between doses with 3 times/day dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anticonvulsant:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3-12 years: Initial: 10-15 mg/kg/day divided into 3 doses/day; titrate dose upward over &sim;3 days; usual dose: Children 3-4 years: 40 mg/kg/day divided into 3 doses/day; children &ge;5 to 12 years: 25-35 mg/kg/day divided into 3 doses/day; doses up to 50 mg/kg/day were well tolerated in one long-term study",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years and Adults: Initial: 300 mg 3 times/day; titrate dose upward if needed; usual dose: 900-1800 mg/day divided into 3 doses/day; doses up to 2400 mg/day divided into 3 doses/day are well tolerated long-term; maximum dose: 3600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuropathic pain:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Limited information is available; some centers use the following doses: Initial: 5 mg/kg/dose at bedtime; day 2: Increase to 5 mg/kg/dose twice daily; day 3: Increase to 5 mg/kg/dose 3 times/day; titrate to effect; usual dosage range: 8-35 mg/kg/day divided into 3 doses/day (Galloway, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Initial: 100 mg 3 times/day; titrate to effect; doses can be increased by 300 mg/day at weekly intervals; doses of at least 900 mg/day appear to be more effective; usual dosage range: 1800-2400 mg/day divided into 3 doses/day; maximum dose: 3600 mg/day (Laird, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Post-herpetic neuralgia: Adults: Initial: Day 1: 300 mg/day; day 2: 300 mg twice daily; day 3: 300 mg 3 times/day; titrate dose as needed for relief of pain to 600 mg 3 times/day; doses of 1800-3600 mg/day have been studied; doses &gt;1800 mg/day did not show additional benefit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;12 years: Dosing in renal impairment has not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: See table",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Gabapentin Dosing Adjustments in Renal Impairment",
"     </caption>",
"     <col align=\"center\" width=\"65\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"74\">",
"     </col>",
"     <col align=\"center\" width=\"74\">",
"     </col>",
"     <col align=\"center\" width=\"74\">",
"     </col>",
"     <col align=\"center\" width=\"73\">",
"     </col>",
"     <col align=\"center\" width=\"65\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Creatinine Clearance",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL/min)",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Total Daily Dose Range",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"5\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Dosage Regimens",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (Maintenance Doses)",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"7\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         &lt;15 mL/minute: Reduce daily dose in proportion to creatinine clearance.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"7\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Supplemental dose should be administered after each 4 hours of hemodialysis (patients on hemodialysis should also receive maintenance doses based on renal function as listed in the upper portion of the table).",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         900-3600",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         3 times/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         3 times/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         600",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         3 times/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         800",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         3 times/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1200 tid",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;30-59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400-1400",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200 twice daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300 twice daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400 twice daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 twice daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         700 twice daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;15-29",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200-700",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200 daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300 daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400 daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500 daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         700 daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-300",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100 daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150 daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200 daily",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300 daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" colspan=\"2\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Hemodialysis",
"          <sup>",
"           2",
"          </sup>",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Posthemodialysis Supplemental Dose",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         125 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         350 mg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 100 mg, 300 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neurontin&reg;: 100 mg, 300 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 250 mg/5 mL (470 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neurontin&reg;: 250 mg/5 mL (470 mL) [cool strawberry-anise flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 600 mg, 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gralise&trade;: 300 mg [contains soybean lecithin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gralise&trade;: 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neurontin&reg;: 600 mg, 800 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [combination package (each unit-dose starter kit contains)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gralise&trade;: 300 mg (9s) [white tablets; contains soybean lecithin] and 600 mg (69s) [beige tablets]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10916634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neurontin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229208.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229208.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gralise&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM245196.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM245196.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to meals; administration with meals may decrease adverse GI effects; dose may be administered as combination of dosage forms; do not administer within 2 hours of magnesium- or aluminum-containing antacids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     One pediatric study (Khurana, 1996) mixed the contents of the capsule in drinks (eg, orange juice) or food (eg, applesauce) for patients who could not swallow the capsule; oral solution is now available",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refrigerate oral solution; store capsules and tablets at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct for treatment of partial seizures with or without secondary generalized seizures (FDA approved in ages &gt;12 years and adults); adjunct for treatment of partial seizures in children (FDA approved in ages 3-12 years); management of post-herpetic neuralgia (FDA approved in adults); also used as adjunct in the treatment of neuropathic pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F175068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Neurontin&reg; may be confused with Motrin&reg;, Neoral&reg;, nitrofurantoin, Noroxin&reg;, Zarontin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F175066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema, vasodilatation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal coordination, abnormal thinking, amnesia, ataxia, depression, dizziness (more common in adults), emotional lability (children), fatigue (more common in adults), fever (children), headache, hostility (children), hyperesthesia, lethargy, nervousness, pain, somnolence (more common in adults), twitching, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite stimulation, constipation, dental abnormalities, diarrhea, dry throat, dyspepsia, flatulence, nausea, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Decreased WBC, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, back pain, dysarthria, fracture, hyperkinesia (children), limb pain, myalgia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctivitis, diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis (children), cough, nasopharyngitis, pharyngitis, respiratory infection (children), rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection, viral infection (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, anemia, angina, angioedema, aphasia, arrhythmias (various), aspiration pneumonia, blindness, bradycardia, breast enlargement, cerebrovascular accident, CNS tumors, coagulation defect, colitis, CPK increased, Cushingoid appearance, encephalopathy, erythema multiforme, facial paralysis, fecal incontinence, gastroenteritis, glaucoma, glycosuria, hearing loss, heart block, heart failure, hematemesis, hematuria, hemiplegia, hemorrhage, hepatitis, hepatomegaly, herpes zoster, hyperlipidemia, hyper-/hypotension, hyper-/hypothyroidism, hyponatremia, jaundice, leukocytosis, liver function tests increased, local myoclonus, lymphadenopathy, lymphocytosis, meningismus, MI, migraine, nephrosis, nerve palsy, non-Hodgkin's lymphoma, ovarian failure, pancreatitis, peptic ulcer, pericardial effusion, pericardial rub, pericarditis, peripheral vascular disorder, pneumonia, psychosis, pulmonary embolus, pulmonary thrombosis, renal stone, retinopathy, skin necrosis, status epilepticus, Stevens-Johnson syndrome, subdural hematoma, suicidal behavior/ideation, syncope, tachycardia, thrombocytopenia, thrombophlebitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gabapentin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and decrease the dose in patients with renal dysfunction; in male (but not female) rats receiving gabapentin, a high incidence of pancreatic acinar adenocarcinoma was noted, the clinical significance in humans is unknown; effectiveness in children &lt;3 years is not established",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neuropsychiatric adverse events, such as emotional lability (eg, behavioral problems), hostility, aggressive behaviors, thought disorder (eg, problems with concentration and school performance) and hyperkinesia (eg, hyperactivity and restlessness), have been reported in pediatric patients. Most of these pediatric neuropsychiatric adverse events are mild to moderate in terms of intensity but discontinuation of gabapentin may be required; children with mental retardation and attention deficit disorders may be at increased risk for behavioral side effects. Abrupt withdrawal may precipitate status epilepticus or increase in seizures; decrease dose gradually over at least 1 week.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5-100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA is requiring that a Medication Guide be developed for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food slightly increases rate and extent of absorption (AUC and peak increase by 14%)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F175008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Gabapentin crosses the placenta. In a small study (n=6), the umbilical/maternal plasma concentration ratio was ~1.74. Neonatal concentrations declined quickly after delivery and at 24 hours of life were ~27% of the cord blood concentrations at birth (gabapentin neonatal half-life ~14 hours) (Ohman, 2005). Outcome data following maternal use of gabapentin during pregnancy is limited (Holmes, 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to gabapentin during pregnancy are encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizure frequency and duration; renal function; weight; behavior in children; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1053086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Minimum effective serum concentration may be 2 mcg/mL;",
"     <b>",
"      routine monitoring of drug levels is not required",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not fully elucidated, most likely binds to an undefined neuroreceptor in the brain that is possibly linked with, or identical to a site resembling the L-system amino acid carrier protein; although structurally similar to the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), gabapentin does not significantly affect the GABA system; it does",
"     <b>",
"      not",
"     </b>",
"     bind to GABA receptors, affect GABA neuronal uptake nor mimic GABA effects",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Very rapid; via an active (ie, facilitated transport) saturable process; dose-dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 50-60 L or 0.65-1.04 L/kg; CSF concentrations are &sim;20% of plasma concentrations; distributes to breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;3% (not clinically significant)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Not metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &sim;60% (300 mg dose given 3 times/day); bioavailability decreases with increasing doses; bioavailability is 27% with 1600 mg dose given 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Infants 1 month to Children 12 years and Adults: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 1 month to Children 12 years: 4.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, normal: 5.3 hours (range: 5-9); increased half-life with decreased renal function; anuric adult patients: 132 hours; adults during hemodialysis: 3.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted unchanged in the urine (75% to 80%) and feces (10% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: (",
"     <b>",
"      Note:",
"     </b>",
"     Apparent oral clearance is directly proportional to Cl",
"     <sub>",
"      cr",
"     </sub>",
"     ): Clearance in infants is highly variable; oral clearance (per kg) in children &lt;5 years of age is higher than in children &ge;5 years of age",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/8/2182?source=see_link\">",
"      see \"Gabapentin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take only as prescribed. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause somnolence, and other symptoms and signs of CNS depression; do not operate machinery or drive a car until you have experience with the drug. Do not discontinue abruptly (an increase in seizure activity may result). Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self-harm. Report persistent side effects, worsening of seizure activity, or loss of seizure control.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gabapentin is not effective for absence seizures; gabapentin does not induce liver enzymes",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F175003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral solution is available (50 mg/mL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 100 mg/mL suspension may be made with tablets (immediate release) and either a 1:1 mixture of Ora-Sweet&reg; (100 mL) and Ora-Plus&reg; (100 mL) or 1:1 mixture of methylcellulose 1% (100 mL) and Simple Syrup N.F. (100 mL). Crush sixty-seven 300 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 200 mL. Label \"shake well\" and \"refrigerate\". Stable for 91 days refrigerated (preferred) or 56 days at room temperature.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andrews CO and Fischer JH, &ldquo;Gabapentin: A New Agent for the Management of Epilepsy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(10):1188-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/23/35191/abstract-text/7841578/pubmed\" id=\"7841578\" target=\"_blank\">",
"        7841578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bourgeois BF, &ldquo;Antiepileptic Drugs in Pediatric Practice,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1995, 36(Suppl 2):S34-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/23/35191/abstract-text/8784213/pubmed\" id=\"8784213\" target=\"_blank\">",
"        8784213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galloway KS and Yaster M, &ldquo;Pain and Symptom Control in Terminally Ill Children,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 2000, 47(3):711-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/23/35191/abstract-text/10835999/pubmed\" id=\"10835999\" target=\"_blank\">",
"        10835999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khurana DS, Riviello J, Helmers S, et al, &ldquo;Efficacy of Gabapentin Therapy in Children With Refractory Partial Seizures,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 128(6):829-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/23/35191/abstract-text/8648543/pubmed\" id=\"8648543\" target=\"_blank\">",
"        8648543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laird MA and Gidal BE, &ldquo;Use of Gabapentin in the Treatment of Neuropathic Pain,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(6):802-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/23/35191/abstract-text/10860142/pubmed\" id=\"10860142\" target=\"_blank\">",
"        10860142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee DO, Steingard RJ, Cesena M, et al, &ldquo;Behavioral Side Effects of Gabapentin in Children,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1996, 37(1):87-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/23/35191/abstract-text/8603631 /pubmed\" id=\"8603631 \" target=\"_blank\">",
"        8603631",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leiderman D, Garofalo E, and LaMoreaux L, &ldquo;Gabapentin Patients With Absence Seizures: Two Double-Blind, Placebo Controlled Studies,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1993, 34(Suppl 6):45 (abstract).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pellock JM, &ldquo;Managing Pediatric Epilepsy Syndromes With New Antiepileptic Drugs,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 104(5 Pt 1):1106-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?34/23/35191/abstract-text/10545555/pubmed\" id=\"10545555\" target=\"_blank\">",
"        10545555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pressler KL, Jabbour JT, Rose DF, et al, &ldquo;Gabapentin and Aggression in Pediatric Patients: A Review of the Literature,&rdquo;",
"      <i>",
"       Journal of Pediatric Pharmacy Practice",
"      </i>",
"      , 1998, 3(2):100-5.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13330 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35191=[""].join("\n");
var outline_f34_23_35191=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175023\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175024\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053083\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053074\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174997\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174981\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10916634\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053088\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053078\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053087\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175068\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175066\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053091\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053073\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053072\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299373\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174990\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053094\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174993\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175008\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053082\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053086\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053071\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053090\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053080\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053092\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175003\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13330|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=related_link\">",
"      Gabapentin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/8/2182?source=related_link\">",
"      Gabapentin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_23_35192="Basic properties of myocardial perfusion agents";
var content_f34_23_35192=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic properties of myocardial perfusion agents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35192/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35192/contributors\">",
"     Thomas A Holly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35192/contributors\">",
"     Preeti Kansal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35192/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35192/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35192/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35192/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/23/35192/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radionuclide myocardial perfusion imaging (MPI) involves the visualization of a radiopharmaceutical that is distributed throughout the myocardium in proportion to coronary blood flow, thereby permitting the determination of relative blood flow in various regions of the heart. Regional coronary blood flow (delivery) determines the amount of tracer activity within a specific area; close correlation between flow and activity has been demonstrated with the currently available radiopharmaceuticals over a physiologic range of coronary blood flow.",
"   </p>",
"   <p>",
"    Perfusion imaging is dependent upon the physical properties of the radiolabeled tracer, its delivery, and its extraction and retention by the myocyte. Both cell membrane integrity and energy utilization are necessary for intracellular extraction and retention of tracer. Thus, retained tracer activity is synonymous with",
"    <strong>",
"     myocyte viability",
"    </strong>",
"    . Revascularization of such segments can lead to improvement in left ventricular function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ideal perfusion agent would have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High first pass myocardial extraction",
"     </li>",
"     <li>",
"      Linear relationship between uptake and flow",
"     </li>",
"     <li>",
"      Uptake independent of metabolic state",
"     </li>",
"     <li>",
"      Stable distribution during imaging",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several radiolabeled myocardial perfusion agents are now available. Understanding the basic properties of these agents is necessary in order to choose the proper agent for a particular clinical setting and to fully understand the results of radionuclide myocardial perfusion imaging (",
"    <a class=\"graphic graphic_table graphicRef60169 \" href=\"UTD.htm?42/21/43356\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10049468\">",
"    <span class=\"h1\">",
"     SPECT TRACERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single photon emission computed tomography (SPECT) is the most commonly used myocardial perfusion imaging technique. Thallium-201 and technetium-99 tracers can be used in SPECT MPI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Thallium-201",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thallium-201 (Tl-201) is a radioactive element that is similar to potassium analogs first used in perfusion imaging, but with superior imaging characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     General characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tl-201 has the following general characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is cyclotron produced and therefore requires off-site manufacturing.",
"     </li>",
"     <li>",
"      The principal photopeaks are gamma rays at 135 keV (2.7 percent) and 167 keV (10 percent), and mercury X-rays of 69 to 83 keV (85 to 90 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The physical half-life of thallium-201 is prolonged (73 hours), limiting the overall amount that can be administered to 2 to 4 mCi.",
"     </li>",
"     <li>",
"      Thallium uptake is partly an active process involving the Na-K-ATPase pump. Due to the relatively small contribution of active transport, extraction and uptake of thallium is relatively unaffected by ischemia, hypoxia, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , and is directly proportional to coronary blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/2-5\">",
"       2-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The relationship between flow, as measured by microspheres, and myocardial thallium activity is linear and proportional up to at least twice the resting flow rates [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thallium uptake may overestimate flow within a region with low flow rates, and underestimate flow at high flow rates [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thallium-201 has the following advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myocardial uptake is proportional to flow.",
"     </li>",
"     <li>",
"      Redistribution allows a single injection for both stress and rest images.",
"     </li>",
"     <li>",
"      It is considered the \"gold standard\" for viability assessment among single photon agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"       \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it also has two disadvantages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low photon energy results in more scatter and soft tissue attenuation.",
"     </li>",
"     <li>",
"      Longer physical half-life limits the allowable dose, which reduces image quality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Redistribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following thallium's initial extraction, there is a continuous exchange between the myocyte and the extracellular compartment, resulting in a phenomenon called redistribution. Intake of thallium into the cell continues via additional extraction of thallium that still remains in the blood (arterial input), and recirculation of tracer that has already been washed out of the intracellular compartment. Thallium may leak out of various regions within the myocardium at different rates, based upon coronary blood flow. Thus, an area that has higher coronary flow may permit the egress of thallium at a faster rate than a region of low flow, demonstrating a \"differential washout\" of thallium.",
"   </p>",
"   <p>",
"    Redistribution often begins as early as 20 minutes following thallium administration (",
"    <a class=\"graphic graphic_figure graphicRef62113 \" href=\"UTD.htm?37/54/38765\">",
"     figure 1",
"    </a>",
"    ) and may result in the partial or total resolution of perfusion defects noted shortly after stress imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, post-stress imaging should begin within 15 minutes after the initial injection. The redistribution process allows thallium to assess the relative regional coronary blood flow following stress, and under \"resting\" conditions, after a single injection of tracer [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the estimate of perfusion is different at three to four hours after thallium delivery than under true resting conditions, and it can overestimate the extent of myocardial necrosis. This potential limitation may be overcome by a second injection of a smaller dose of thallium immediately following the redistribution images (\"reinjection\"). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thallium redistribution can be affected by several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changes in coronary blood flow can have a substantial impact upon redistribution, although tracer may be redistributed even without a significant alteration in flow.",
"     </li>",
"     <li>",
"      The administration of nitrates appears to facilitate the appearance of thallium redistribution, and consequently the recognition of reversible myocardial ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Redistribution may be affected by metabolic interventions that alter the transport of thallium (eg, ribose administration), potentially permitting earlier and more obvious determination of redistribution after an ischemic event [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Reverse redistribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many authors have commented on a finding referred to as \"reverse redistribution,\" in which the perfusion defect appears worse on the delayed redistribution perfusion images (three to four hours after thallium injection) than on the initial images. This phenomenon is thought to be related to hyperemic blood flow that causes enhanced uptake of thallium on initial post-stress images [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/11\">",
"     11",
"    </a>",
"    ], and a more rapid clearance of thallium, producing the appearance of a perfusion abnormality.",
"   </p>",
"   <p>",
"    Reverse redistribution is consistent with viable myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/12\">",
"     12",
"    </a>",
"    ]. However, its presence in a patient with a low likelihood of ischemia and without other evidence of ischemia is felt to represent an artifact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Technetium-99 labeled agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several physical advantages for the use of technetium-99m (Tc-99m) perfusion tracers (",
"    <a class=\"graphic graphic_table graphicRef67709 \" href=\"UTD.htm?10/38/10859\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The higher photon energy (140 keV) is well suited for gamma camera imaging and may result in less photon attenuation and scatter due to soft tissue when compared with thallium-201. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25768?source=see_link\">",
"       \"Attenuation artifact in SPECT radionuclide myocardial perfusion imaging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A half-life of six hours and favorable dosimetry permits the administration of substantially more activity, thereby resulting in a high number of emitted photons and improved image resolution. The increased photon flux also permits functional imaging with gated single photon emission computed tomography (SPECT) or first-pass techniques.",
"     </li>",
"     <li>",
"      Tc-99m is a generator produced product and as a result, it is readily available (on site) at most institutions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three 99m Tc-labeled myocardial perfusion agents are now available in clinical practice (sestamibi, tetrofosmin, and teboroxime), but only the first two are commonly used. Each compound has unique properties that make it suitable for certain types of imaging (",
"    <a class=\"graphic graphic_table graphicRef60169 \" href=\"UTD.htm?42/21/43356\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sestamibi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tc-99m sestamibi (Cardiolite&trade;) is in a class of compounds known as isonitriles. Sestamibi has the following general characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is a lipophilic monovalent cation with transient hepatic uptake, minimal lung uptake, and a good target-to-background ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The exact mechanism of myocardial uptake of sestamibi is unclear. Uptake appears to be passive across the plasma and mitochondrial membranes with sestamibi being sequestered in the mitochondria by the large negative membrane potential [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/14\">",
"       14",
"      </a>",
"      ]. In experimental models, sestamibi uptake is not blocked by ouabain. Thus, unlike thallium uptake, sestamibi uptake is not dependent upon the Na-K-ATPase pump [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/3,15\">",
"       3,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The fraction of sestamibi extracted on first pass by the heart is lower than that for thallium [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Distribution within the myocardium is proportional to blood flow until approximately two to three times the resting flow levels, when uptake starts to plateau [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Animal models show that sestamibi myocardial activity overestimates coronary flow at low flow rates, as determined by radiolabeled microspheres [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/17\">",
"       17",
"      </a>",
"      ]. This finding may be attributed to increased extraction of tracers at low flow and, as mentioned above, has also been seen with Tl-201.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tc-99m sestamibi has the following advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myocardial uptake is proportional to flow",
"     </li>",
"     <li>",
"      There is stable retention of tracer (minimal redistribution)",
"     </li>",
"     <li>",
"      Simultaneous perfusion and function assessment is possible",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sestamibi undergoes minimal redistribution over time [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. This stable distribution has numerous ramifications for the use of this agent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sestamibi is well suited to the prolonged acquisition times associated with tomographic imaging.",
"     </li>",
"     <li>",
"      The absence of significant sestamibi redistribution necessitates two separate injections of the radiopharmaceutical, one during peak stress and a second while at rest.",
"     </li>",
"     <li>",
"      The lack of sestamibi redistribution permits greater flexibility in scheduling since imaging is not mandated immediately after injection.",
"     </li>",
"     <li>",
"      Sestamibi can be used to quantify the area of risk in a patient suffering an acute myocardial infarction. As an example, sestamibi can be injected at the time of presentation, and the patient imaged after stabilization in the coronary care unit. Since sestamibi activity reflects myocardial perfusion at the time of injection, defects on these early images indicate the \"area at risk.\" Subsequent injections and imaging after interventions (eg, thrombolysis) can then be used to demonstrate the amount of salvaged myocardium [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sestamibi can be given to patients with chest pain and nondiagnostic findings on ECG, and images taken later, even after treatment of the chest pain (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71950 \" href=\"UTD.htm?26/57/27550\">",
"       image 1",
"      </a>",
"      ). This method permits assessment of coronary blood flow at the time of chest pain, allowing for improved triage and management. As an example, a patient with a normal perfusion study after being injected with sestamibi during an episode of chest pain may be triaged to a less intensive care setting or even home, depending upon the clinical circumstances.",
"     </li>",
"     <li>",
"      The stable retention and high count rates of Tc-99m sestamibi permits the evaluation of left ventricular function as part of a perfusion imaging protocol. Both gated SPECT and first pass imaging have been performed successfully with this agent [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/20\">",
"       20",
"      </a>",
"      ]. This evaluation may be one of the most valuable clinical attributes of sestamibi scintigraphy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the lack of redistribution would appear to limit the use of Tc-99m sestamibi for the evaluation of myocardial viability and the detection of hibernating myocardium, this does not appear to be the case [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. There are data to suggest that quantitative analysis of sestamibi activity is useful for predicting functional recovery of dysfunctional ventricular segments after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, nitrate administration prior to tracer injection improves the detection of viable myocardium by reducing the perfusion defect size and intensity in the majority of viable regions [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Tetrofosmin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetrofosmin (Myoview&trade;) is a lipophilic, cationic diphosphine compound. It has good myocardial uptake with rapid clearance from the liver, lungs, and blood [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The mechanism of uptake into the myocytes is not clear but appears to involve potential driven diffusion across the sarcolemmal and mitochondrial membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important features of Tc-99m tetrofosmin include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myocardial uptake is proportional to flow",
"     </li>",
"     <li>",
"      Minimal redistribution occurs",
"     </li>",
"     <li>",
"      There may be more rapid washout from the liver than with sestamibi, permitting earlier imaging after injection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Myocardial uptake of tetrofosmin is proportional to microsphere confirmed blood flow until uptake plateaus at flow rates greater than 2.0",
"    <span class=\"nowrap\">",
"     mL/min/g",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/28\">",
"     28",
"    </a>",
"    ]. As with sestamibi, there is little myocardial washout over time. Thus, high quality myocardial images can be obtained from five minutes to several hours after injection. The more rapid clearance from the liver with tetrofosmin may lead to less artifact from subdiaphragmatic activity, which is a common problem with Tc-99m sestamibi [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there is less widespread experience with tetrofosmin compared with the other available agents, the diagnostic accuracy of stress Tc-99m tetrofosmin imaging appears to be similar to that of Tl-201 and Tc-99m sestamibi [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Given the many similarities between tetrofosmin and sestamibi, these two agents can be used in clinically similar situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise tetrofosmin imaging is of prognostic value in patients with coronary heart disease, adding incremental information to that provided by clinical and exercise data [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. In a multicenter review of 4278 patients, the mortality rate in those with a normal exercise or adenosine tetrofosmin SPECT study was 0.6 percent per year, similar to published rates for normal thallium and sestamibi studies [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link&amp;anchor=H9#H9\">",
"       \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\", section on 'Exercise ECG testing with imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some studies utilizing vasodilator stress have shown that, compared with thallium and sestamibi, tetrofosmin detected fewer ischemic segments, and the extent and severity of reversible defects were smaller. As a result, tetrofosmin may be less sensitive in identifying mild coronary stenoses [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tetrofosmin appears to be useful for the detection of viable myocardium [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. In one report, its ability to predict functional recovery after percutaneous revascularization in patients with a prior myocardial infarction was comparable to that of thallium and sestamibi [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      First pass imaging is feasible, and gated SPECT tetrofosmin imaging can also be performed [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preliminary studies have revealed that tetrofosmin is of clinical utility in patients who present to emergency departments with chest pain and nondiagnostic electrocardiograms [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Teboroxime",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teboroxime (Cardiotec&trade;) is a neutral, lipophilic perfusion agent in a class of compounds called the boronic acid adducts of technetium dioxime (BATO). The uptake mechanism is unknown, but data suggest it is passive, with binding to intact lipid membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Teboroxime differs from thallium and sestamibi in that its uptake appears to be relatively insensitive to myocardial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/15,42,43\">",
"     15,42,43",
"    </a>",
"    ]. As a result, teboroxime may serve as a pure blood flow agent that is not dependent upon cellular viability. In contrast to sestamibi, teboroxime is characterized by rapid uptake and washout, with a clearance half-time in the myocardium of only a few minutes.",
"   </p>",
"   <p>",
"    These properties have led to interesting possibilities for use but also to a lack of clinical utility due to difficulties in imaging.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The peak extraction of teboroxime is the highest of any perfusion agent that has been evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. The early uptake of teboroxime is proportional to flow up to 4.5",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per g, a level at which thallium and sestamibi would underestimate true flow (",
"      <a class=\"graphic graphic_figure graphicRef77278 \" href=\"UTD.htm?40/9/41117\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. Thus, teboroxime appears to be a more accurate marker of flow than the other tracers at high flow rates and may prove useful for quantitation of coronary blood flow.",
"     </li>",
"     <li>",
"      The washout of teboroxime from the myocardium is rapid and flow-dependent. Studies in models of partial stenosis have demonstrated faster washout from normal segments than from ischemic segments [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/48\">",
"       48",
"      </a>",
"      ]. This decreased clearance from ischemic areas relative to normally perfused zones gives the impression of \"redistribution\" on serial imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The short myocardial residence time of teboroxime necessitates rapid patient positioning and image acquisition, which increases the difficulty of testing [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. In addition, the lower count rates with such rapid imaging protocols preclude the use of gated SPECT imaging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10050186\">",
"    <span class=\"h1\">",
"     PET TRACERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET) imaging differs from single photon emission computed tomography (SPECT) in that PET uses radionuclides that decay by positron emission. PET imaging relies on the detection of two 511 keV gamma photons. Typical PET tracers have short half-lives; they must be synthesized and imaged in a short period of time. Like SPECT tracers, PET tracers also must be easily accessible, cost effective, and have a linear extraction over a wide range of myocardial flow.",
"   </p>",
"   <p>",
"    The most commonly used cardiac PET tracers are Rubidium-82 (Rb-82), Nitrogen-13 (N-13), Oxygen-15 (O-15), and Fluorine-18 (F-18). PET imaging is based on two concepts: myocardial flow and myocardial metabolism. Rb-82, N-13 ammonia, and O-15 water all allow an assessment of myocardial flow, while F-18 fluorodeoxyglucose (FDG) allows an assessment of myocardial metabolism.",
"   </p>",
"   <p>",
"    <strong>",
"     Rubidium-82",
"    </strong>",
"    &mdash; Rubidium-82, like thallium, is a potassium analog. It is also dependent on the",
"    <span class=\"nowrap\">",
"     Na+/K+",
"    </span>",
"    ATPase pump for cellular uptake, and its myocardial extraction is similar to that of thallium. The following characteristics make Rb-82 a clinically useful cardiac PET imaging tracer:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is generator produced",
"     </li>",
"     <li>",
"      It has a short half-life",
"     </li>",
"     <li>",
"      It allows high throughput for clinical pharmacologic stress testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike thallium, rubidium is generator-produced, allowing it to be manufactured on site. It is eluted from the decay of strontium-82 in a generator, which must be replaced approximately every four weeks. Rb-82 decays by positron emission with a half-life of only 78 seconds. Although this short half-life makes the logistics of imaging challenging, it also allows for the rapid completion of a series of rest and stress imaging studies. The cost of the generator is often a fixed monthly expense, making it economically feasible for larger volume centers.",
"   </p>",
"   <p>",
"    In comparison to SPECT imaging with thallium, Rb-82 based PET imaging has shown a higher overall sensitivity, specificity, and accuracy for the detection of coronary disease. Additionally, the improved image quality with PET tracers such as Rb-82 resulted in a reduction in the number of \"probably normal\" or abnormal studies by SPECT versus PET (37 versus 21 percent).",
"   </p>",
"   <p>",
"    In a small series, Rb-82 has been shown to identify multivessel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/52\">",
"     52",
"    </a>",
"    ]. When used to measure myocardial flow reserve, Rb-82 PET can predict the likelihood of multivessel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, several studies in both patient volunteers and animals have compared Rb-82 with N-13 ammonia and shown that Rb-82 can be useful in the quantification of myocardial blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Fluorine-18",
"    </strong>",
"    &mdash; Using F-18, one can create FDG (fluorodeoxyglucose), which is a radiolabeled glucose analog used for metabolic and perfusion imaging, allowing one to distinguish ischemic myocardium from non viable myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/56\">",
"     56",
"    </a>",
"    ]. The half-life of F-18 is 110 minutes, and it must be produced in a cyclotron.",
"   </p>",
"   <p>",
"    The use of FDG was initially reported in 1986 for the assessment of myocardial viability [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/57\">",
"     57",
"    </a>",
"    ]. In patients with poor ventricular function, FDG-PET showed an increased benefit over thallium or sestamibi imaging in improvement of ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/58\">",
"     58",
"    </a>",
"    ]. Since that time, there have been increasing data on the prognostic utility of FDG after coronary revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Nitrogen-13",
"    </strong>",
"    &mdash; As nitrogen is an essential component of basic amino acids, N-13 allows the labeling of amino acids without altering their physiologic properties. These amino acids are important components to myocardial protein synthesis and metabolism in both normal and diseased states. The neutral component diffuses across the cell membranes where it re-equilibrates with ammonium and becomes trapped intracellularly. In vitro studies have shown that in ischemic myocardium, more N-13 becomes trapped within myocytes with a diminished washout of the tracer [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    N-13 allows gating of both rest and stress images in addition to quantification of myocardial blood flow. In small studies, quantitative myocardial blood flow with N-13 was reproducible and accurate when compared with estimates using Rb-82 [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/61\">",
"     61",
"    </a>",
"    ]. Its limitations are that it has a short half-life (10 minutes) and is cyclotron produced, and its use requires coordination of a cyclotron operator, a radiochemist, and a stress testing technologist. This short half-life however results in decreased radiation exposure to the patient.",
"   </p>",
"   <p>",
"    Additionally, N-13 PET perfusion and flow reserve have long-term prognostic value. Individuals with abnormal coronary flow reserve measured by N-13 PET had significantly higher rates of major cardiac events over a five-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Oxygen-15",
"    </strong>",
"    &mdash; O-15 is important because its ability to freely diffuse across the cell membrane makes it useful for imaging myocardial blood flow. However, its utility is limited by its extremely short half-life of only two minutes and because it is cyclotron produced. It is currently not approved for clinical use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the ideal myocardial perfusion agent has not been discovered, several single photon agents are currently available with differing physical properties and applications (",
"    <a class=\"graphic graphic_table graphicRef60169 \" href=\"UTD.htm?42/21/43356\">",
"     table 1",
"    </a>",
"    ). By understanding the characteristics of these radiopharmaceuticals, appropriate selection of the agent may be accomplished and imaging protocols optimized.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thallium-201 has the following advantages and disadvantages:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Myocardial uptake is proportional to flow.",
"     </li>",
"     <li>",
"      Redistribution allows a single injection for both stress and rest images.",
"     </li>",
"     <li>",
"      It is considered the \"gold standard\" for viability assessment among single photon agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link\">",
"       \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low photon energy results in more scatter and soft tissue attenuation.",
"     </li>",
"     <li>",
"      Longer physical half-life limits the allowable dose which reduces image quality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Technetium-99m (Tc-99m) perfusion tracers have several advantages (",
"      <a class=\"graphic graphic_table graphicRef67709 \" href=\"UTD.htm?10/38/10859\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The higher photon energy (140 keV) is well suited for gamma camera imaging, and may result in less photon attenuation and scatter due to soft tissue when compared with thallium-201. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25768?source=see_link\">",
"       \"Attenuation artifact in SPECT radionuclide myocardial perfusion imaging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A half-life of six hours and favorable dosimetry permits the administration of substantially more activity, thereby resulting in a high number of emitted photons and improved image resolution. The increased photon flux also permits functional imaging with gated single photon emission computed tomography (SPECT) or first-pass techniques.",
"     </li>",
"     <li>",
"      Tc-99m is a generator produced product, and as a result, it is readily available (on site) at most institutions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positron emission tomography (PET) imaging differs from single photon emission computed tomography (SPECT) in that PET uses radionuclides that decay by positron emission. PET imaging relies on the detection of two 511 keV gamma photons. Typical PET tracers have short half-lives; they must be synthesized and imaged in a short period of time. The most commonly used cardiac PET tracers are Rubidium-82 (Rb-82), Nitrogen-13 (N-13), Oxygen-15 (O-15), and Fluorine-18 (F-18). PET imaging is based on two concepts: myocardial flow and myocardial metabolism. Rb-82, N-13 ammonia, and O-15 water all allow an assessment of myocardial flow, while F-18 fluorodeoxyglucose (FDG) allows an assessment of myocardial metabolism.",
"      <br/>",
"      <br/>",
"      For the routine detection and evaluation of coronary artery disease, thallium and technetium-99m agents have proven efficacy and are comparable in terms of diagnostic accuracy [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35192/abstract/63\">",
"       63",
"      </a>",
"      ]. The technetium-99m agents provide improved image quality and more easily permit simultaneous assessment of ventricular function at a lower radiation dose. However, the choice of agent and protocol will depend upon the needs and requirements of the particular nuclear cardiology laboratory (eg, scheduling, availability, etc).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/1\">",
"      Lebowitz E, Greene MW, Fairchild R, et al. Thallium-201 for medical use. I. J Nucl Med 1975; 16:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/2\">",
"      Leppo JA, Macneil PB, Moring AF, Apstein CS. Separate effects of ischemia, hypoxia, and contractility on thallium-201 kinetics in rabbit myocardium. J Nucl Med 1986; 27:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/3\">",
"      Meerdink DJ, Leppo JA. Comparison of hypoxia and ouabain effects on the myocardial uptake kinetics of technetium-99m hexakis 2-methoxyisobutyl isonitrile and thallium-201. J Nucl Med 1989; 30:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/4\">",
"      Strauss HW, Harrison K, Langan JK, et al. Thallium-201 for myocardial imaging. Relation of thallium-201 to regional myocardial perfusion. Circulation 1975; 51:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/5\">",
"      Nielsen AP, Morris KG, Murdock R, et al. Linear relationship between the distribution of thallium-201 and blood flow in ischemic and nonischemic myocardium during exercise. Circulation 1980; 61:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/6\">",
"      Mays AE Jr, Cobb FR. Relationship between regional myocardial blood flow and thallium-201 distribution in the presence of coronary artery stenosis and dipyridamole-induced vasodilation. J Clin Invest 1984; 73:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/7\">",
"      Pohost GM, Zir LM, Moore RH, et al. Differentiation of transiently ischemic from infarcted myocardium by serial imaging after a single dose of thallium-201. Circulation 1977; 55:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/8\">",
"      Beller GA, Watson DD, Ackell P, Pohost GM. Time course of thallium-201 redistribution after transient myocardial ischemia. Circulation 1980; 61:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/9\">",
"      Medrano R, Mahmarian J, Verani M. Nitroglycerine before injection of thallium-201 enhances detection of reversible hypoperfusion via collateral blood flow: A randomized, double blind parallel, placebo-controlled trial using quantitative tomography (abstract). J Am Coll Cardiol 1993; 21:221A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/10\">",
"      Perlmutter NS, Wilson RA, Angello DA, et al. Ribose facilitates thallium-201 redistribution in patients with coronary artery disease. J Nucl Med 1991; 32:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/11\">",
"      Weiss AT, Maddahi J, Lew AS, et al. Reverse redistribution of thallium-201: a sign of nontransmural myocardial infarction with patency of the infarct-related coronary artery. J Am Coll Cardiol 1986; 7:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/12\">",
"      Soufer R, Dey HM, Lawson AJ, et al. Relationship between reverse redistribution on planar thallium scintigraphy and regional myocardial viability: a correlative PET study. J Nucl Med 1995; 36:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/13\">",
"      Wackers FJ, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989; 30:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/14\">",
"      Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/15\">",
"      Maublant JC, Moins N, Gachon P, et al. Uptake of technetium-99m-teboroxime in cultured myocardial cells: comparison with thallium-201 and technetium-99m-sestamibi. J Nucl Med 1993; 34:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/16\">",
"      Leppo JA, Meerdink DJ. Comparison of the myocardial uptake of a technetium-labeled isonitrile analogue and thallium. Circ Res 1989; 65:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/17\">",
"      Glover DK, Okada RD. Myocardial kinetics of Tc-MIBI in canine myocardium after dipyridamole. Circulation 1990; 81:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/18\">",
"      Okada RD, Glover D, Gaffney T, Williams S. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile. Circulation 1988; 77:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/19\">",
"      Sinusas AJ, Trautman KA, Bergin JD, et al. Quantification of area at risk during coronary occlusion and degree of myocardial salvage after reperfusion with technetium-99m methoxyisobutyl isonitrile. Circulation 1990; 82:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/20\">",
"      DePuey EG, Rozanski A. Using gated technetium-99m-sestamibi SPECT to characterize fixed myocardial defects as infarct or artifact. J Nucl Med 1995; 36:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/21\">",
"      Udelson JE, Coleman PS, Metherall J, et al. Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. Circulation 1994; 89:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/22\">",
"      Maurea S, Cuocolo A, Soricelli A, et al. Enhanced detection of viable myocardium by technetium-99m-MIBI imaging after nitrate administration in chronic coronary artery disease. J Nucl Med 1995; 36:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/23\">",
"      Bisi G, Sciagr&agrave; R, Santoro GM, et al. Technetium-99m-sestamibi imaging with nitrate infusion to detect viable hibernating myocardium and predict postrevascularization recovery. J Nucl Med 1995; 36:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/24\">",
"      Sciagr&agrave; R, Bisi G, Santoro GM, et al. Comparison of baseline-nitrate technetium-99m sestamibi with rest-redistribution thallium-201 tomography in detecting viable hibernating myocardium and predicting postrevascularization recovery. J Am Coll Cardiol 1997; 30:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/25\">",
"      Higley B, Smith FW, Smith T, et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993; 34:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/26\">",
"      Jain D, Wackers FJ, Mattera J, et al. Biokinetics of technetium-99m-tetrofosmin: myocardial perfusion imaging agent: implications for a one-day imaging protocol. J Nucl Med 1993; 34:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/27\">",
"      Platts EA, North TL, Pickett RD, Kelly JD. Mechanism of uptake of technetium-tetrofosmin. I: Uptake into isolated adult rat ventricular myocytes and subcellular localization. J Nucl Cardiol 1995; 2:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/28\">",
"      Sinusas AJ, Shi Q, Saltzberg MT, et al. Technetium-99m-tetrofosmin to assess myocardial blood flow: experimental validation in an intact canine model of ischemia. J Nucl Med 1994; 35:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/29\">",
"      Zaret BL, Rigo P, Wackers FJ, et al. Myocardial perfusion imaging with 99mTc tetrofosmin. Comparison to 201Tl imaging and coronary angiography in a phase III multicenter trial. Tetrofosmin International Trial Study Group. Circulation 1995; 91:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/30\">",
"      Borges-Neto S, Tuttle RH, Shaw LK, et al. Outcome prediction in patients at high risk for coronary artery disease: comparison between 99mTc tetrofosmin and 99mTc sestamibi. Radiology 2004; 232:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/31\">",
"      Flamen P, Bossuyt A, Franken PR. Technetium-99m-tetrofosmin in dipyridamole-stress myocardial SPECT imaging: intraindividual comparison with technetium-99m-sestamibi. J Nucl Med 1995; 36:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/32\">",
"      Shaw LJ, Hendel R, Borges-Neto S, et al. Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. J Nucl Med 2003; 44:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/33\">",
"      Galassi AR, Azzarelli S, Tomaselli A, et al. Incremental prognostic value of technetium-99m-tetrofosmin exercise myocardial perfusion imaging for predicting outcomes in patients with suspected or known coronary artery disease. Am J Cardiol 2001; 88:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/34\">",
"      Shanoudy H, Raggi P, Beller GA, et al. Comparison of technetium-99m tetrofosmin and thallium-201 single-photon emission computed tomographic imaging for detection of myocardial perfusion defects in patients with coronary artery disease. J Am Coll Cardiol 1998; 31:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/35\">",
"      Soman P, Taillefer R, DePuey EG, et al. Enhanced detection of reversible perfusion defects by Tc-99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease. J Am Coll Cardiol 2001; 37:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/36\">",
"      Koplan BA, Beller GA, Ruiz M, et al. Comparison between thallium-201 and technetium-99m-tetrofosmin uptake with sustained low flow and profound systolic dysfunction. J Nucl Med 1996; 37:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/37\">",
"      Galassi AR, Tamburino C, Grassi R, et al. Comparison of technetium 99m-tetrofosmin and thallium-201 single photon emission computed tomographic imaging for the assessment of viable myocardium in patients with left ventricular dysfunction. J Nucl Cardiol 1998; 5:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/38\">",
"      Acampa W, Cuocolo A, Petretta M, et al. Tetrofosmin imaging in the detection of myocardial viability in patients with previous myocardial infarction: comparison with sestamibi and Tl-201 scintigraphy. J Nucl Cardiol 2002; 9:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/39\">",
"      Takahashi N, Tamaki N, Tadamura E, et al. Combined assessment of regional perfusion and wall motion in patients with coronary artery disease with technetium 99m tetrofosmin. J Nucl Cardiol 1994; 1:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/40\">",
"      Heller GV, Stowers SA, Hendel RC, et al. Acute emergency department Tc-99m tetrofosmin SPECT imaging in patients with chest pain and nondiagnostic ECG: Results of a multicenter trial (abstract). Circulation 1996; 94:I.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/41\">",
"      Rumsey WL, Rosenspire KC, Nunn AD. Myocardial extraction of teboroxime: effects of teboroxime interaction with blood. J Nucl Med 1992; 33:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/42\">",
"      Stone JA, Dawood F, Wen W-H, et al. Is the myocardial uptake of teboroxime viability dependent? (abstract) Circulation 1992; 86:I-707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/43\">",
"      Heller LI, Villegas BJ, Reinhardt CP, et al. Teboroxime is a marker of reperfusion after myocardial infarction. J Nucl Cardiol 1996; 3:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/44\">",
"      Leppo JA, Meerdink DJ. Comparative myocardial extraction of two technetium-labeled BATO derivatives (SQ30217, SQ32014) and thallium. J Nucl Med 1990; 31:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/45\">",
"      Stewart RE, Schwaiger M, Hutchins GD, et al. Myocardial clearance kinetics of technetium-99m-SQ30217: a marker of regional myocardial blood flow. J Nucl Med 1990; 31:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/46\">",
"      Beanlands R, Muzik O, Nguyen N, et al. The relationship between myocardial retention of technetium-99m teboroxime and myocardial blood flow. J Am Coll Cardiol 1992; 20:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/47\">",
"      Di Rocco RJ, Rumsey WL, Kuczynski BL, et al. Measurement of myocardial blood flow using a co-injection technique for technetium-99m-teboroxime, technetium-96-sestamibi and thallium-201. J Nucl Med 1992; 33:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/48\">",
"      Stewart RE, Heyl B, O'Rourke RA, et al. Demonstration of differential post-stenotic myocardial technetium-99m-teboroxime clearance kinetics after experimental ischemia and hyperemic stress. J Nucl Med 1991; 32:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/49\">",
"      Hendel RC, McSherry B, Karimeddini M, Leppo JA. Diagnostic value of a new myocardial perfusion agent, teboroxime (SO 30,217), utilizing a rapid planar imaging protocol: preliminary results. J Am Coll Cardiol 1990; 16:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/50\">",
"      Dahlberg ST, Weinstein H, Hendel RC, et al. Planar myocardial perfusion imaging with technetium-99m-teboroxime: comparison by vascular territory with thallium-201 and coronary angiography. J Nucl Med 1992; 33:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/51\">",
"      Chua T, Kiat H, Germano G, et al. Rapid back to back adenosine stress/rest technetium-99m teboroxime myocardial perfusion SPECT using a triple-detector camera. J Nucl Med 1993; 34:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/52\">",
"      Anagnostopoulos C, Almonacid A, El Fakhri G, et al. Quantitative relationship between coronary vasodilator reserve assessed by 82Rb PET imaging and coronary artery stenosis severity. Eur J Nucl Med Mol Imaging 2008; 35:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/53\">",
"      Ziadi MC, Beanlands RS. The clinical utility of assessing myocardial blood flow using positron emission tomography. J Nucl Cardiol 2010; 17:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/54\">",
"      Lortie M, Beanlands RS, Yoshinaga K, et al. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 2007; 34:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/55\">",
"      Lautam&auml;ki R, George RT, Kitagawa K, et al. Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosis. Eur J Nucl Med Mol Imaging 2009; 36:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/56\">",
"      Schlyer DJ. PET tracers and radiochemistry. Ann Acad Med Singapore 2004; 33:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/57\">",
"      Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/58\">",
"      vom Dahl J, Altehoefer C, Sheehan FH, et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nucl Med 1997; 38:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/59\">",
"      Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/60\">",
"      Henze E, Schelbert HR, Barrio JR, et al. Evaluation of myocardial metabolism, with N-13- and C-11-labeled amino acids and positron computed tomography. J Nucl Med 1982; 23:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/61\">",
"      El Fakhri G, Kardan A, Sitek A, et al. Reproducibility and accuracy of quantitative myocardial blood flow assessment with (82)Rb PET: comparison with (13)N-ammonia PET. J Nucl Med 2009; 50:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/62\">",
"      Herzog BA, Husmann L, Valenta I, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009; 54:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35192/abstract/63\">",
"      Kapur A, Latus KA, Davies G, et al. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study. Eur J Nucl Med Mol Imaging 2002; 29:1608.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1491 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35192=[""].join("\n");
var outline_f34_23_35192=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10049468\">",
"      SPECT TRACERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Thallium-201",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - General characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Redistribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reverse redistribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Technetium-99 labeled agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sestamibi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Tetrofosmin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Teboroxime",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10050186\">",
"      PET TRACERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1491\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1491|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/57/27550\" title=\"diagnostic image 1\">",
"      Sestamibi coronary ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1491|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/54/38765\" title=\"figure 1\">",
"      Redistribution of thallium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/9/41117\" title=\"figure 2\">",
"      Teboroxime and coronary flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1491|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/21/43356\" title=\"table 1\">",
"      SPECT myocardial perfusion agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/38/10859\" title=\"table 2\">",
"      Thallium v technetium imaging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25768?source=related_link\">",
"      Attenuation artifact in SPECT radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_23_35193="Dermatitis herpetiformis histopathology";
var content_f34_23_35193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subepidermal blistering, neutrophilic microabscesses, and a perivascular inflammatory infiltrate are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Florell, MD, Department of Dermatology, University of Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35193=[""].join("\n");
var outline_f34_23_35193=null;
var title_f34_23_35194="Assessment and treatment of ankylosing spondylitis in adults";
var content_f34_23_35194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment and treatment of ankylosing spondylitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35194/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35194/contributors\">",
"     David T Yu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35194/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35194/contributors\">",
"     Joachim Sieper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?34/23/35194/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?34/23/35194/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?34/23/35194/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankylosing spondylitis (AS) is a chronic inflammatory disease manifested by back pain and progressive spinal stiffness. It belongs to the axial group of the spondyloarthritis family of arthritis (SpA). AS characteristically affects young adults with a peak age of onset between 20 and 30 years. Although classically thought of as a spinal disease, transient acute arthritis of peripheral joints occurs in up to 50 percent of patients. In addition, other organs, such as the eyes, lungs, heart, and kidneys can be affected.",
"   </p>",
"   <p>",
"    The assessment, monitoring, prognosis, and treatment of ankylosing spondylitis in adults are presented here. The clinical manifestations and diagnosis of ankylosing spondylitis in adults, and a detailed discussion of the clinical manifestations, approach to diagnosis, pathogenesis, and treatment of SpA in children are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link\">",
"     \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=see_link\">",
"     \"Spondyloarthropathy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of management for patients with AS is to maximize long term health-related quality of life through the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic relief &mdash; To eliminate, or reduce to the minimum level possible, symptoms such as pain, stiffness, and fatigue.",
"     </li>",
"     <li>",
"      Restoration of function &mdash; To return the patient to the best possible functional capacity.",
"     </li>",
"     <li>",
"      Prevention of complications of spinal disease &mdash; To prevent flexion contractures especially of the cervical spine.",
"     </li>",
"     <li>",
"      Minimizing extraspinal and extraarticular manifestations &mdash; To reduce the impact of AS-associated disorders such as uveitis and aortic valve insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach to achieving these goals is outlined in the following discussion. Our recommendations are generally consistent with those jointly developed by the Assessments in Ankylosing Spondylitis International Society (ASAS) and the European League against Rheumatism (EULAR) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Management of AS is life-long for each patient, and shared decision-making by patients and their clinicians is important in management.",
"   </p>",
"   <p>",
"    The symptoms of AS and the rate of progression fluctuate with time and can vary substantially between patients. Functional limitations can result directly from disease activity but also indirectly from the feelings of helplessness and depression, which may be associated with disease activity and which also require recognition and appropriate treatment intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41273?source=see_link\">",
"     \"Psychosocial factors and rheumatic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment decisions depend upon an accurate assessment of disease impact (",
"    <a class=\"graphic graphic_table graphicRef76447 \" href=\"UTD.htm?27/57/28571\">",
"     table 1",
"    </a>",
"    ). In general, four approaches are required:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Information is elicited in the medical history to assess the degree of disease activity, functional disability, and health-related quality of life.",
"     </li>",
"     <li>",
"      Physical examination is used to detect inflammation, contractures and limitations in range of motion.",
"     </li>",
"     <li>",
"      Blood tests are used to assist in assessing disease activity.",
"     </li>",
"     <li>",
"      Imaging is used to assess skeletal damage and, in some patients, disease activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24895086\">",
"    <span class=\"h2\">",
"     Patient history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history is used to assess disease activity, functional disability and health-related status. The following parameters are recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient global assessment on a scale of 0 to 10 or (1 to 10).",
"     </li>",
"     <li>",
"      The physician global assessment on a scale of 1 (mild) to 4 (severe).",
"     </li>",
"     <li>",
"      The BASDAI disease activity questionnaire (",
"      <a class=\"graphic graphic_table graphicRef57638 \" href=\"UTD.htm?13/19/13629\">",
"       table 2",
"      </a>",
"      ) &mdash; It is available in several languages at the websites of the",
"      <a class=\"external\" href=\"file://www.spondylitis.org/\">",
"       Spondylitis Association of America",
"      </a>",
"      (",
"      <a class=\"external\" href=\"file://www.spondylitis.org/\">",
"       www.spondylitis.org",
"      </a>",
"      ) and",
"      <a class=\"external\" href=\"file://www.asas-group.org/\">",
"       Assessment of SpondyloArthritis International Society",
"      </a>",
"      (",
"      <a class=\"external\" href=\"file://www.asas-group.org/\">",
"       www.asas-group.org",
"      </a>",
"      ). It consists of six questions concerning overall symptoms during the week immediately prior to answering the questions, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      1. How would you describe the overall level of",
"      <span class=\"nowrap\">",
"       fatigue/tiredness",
"      </span>",
"      you have experienced?",
"     </li>",
"     <li>",
"      2. How would you describe the overall level of AS neck, back or hip pain you have had?",
"     </li>",
"     <li>",
"      3. How would you describe the overall level of",
"      <span class=\"nowrap\">",
"       pain/swelling",
"      </span>",
"      in joints other than neck, back, hips you have had?",
"     </li>",
"     <li>",
"      4. How would you describe the level of discomfort you have had from an area tender to touch or pressure?",
"     </li>",
"     <li>",
"      5. How would you describe the level of morning stiffness you have had from the time you wake up?",
"     </li>",
"     <li>",
"      6. How long does your morning stiffness last from the time you wake up?",
"      <br/>",
"      <br/>",
"      Each question is scored on a scale of 0-10. Except for the last question, 0 indicates none and 10 indicate very severe. For the last question, 0 is 0 hours, 5 is one hour, and 10 is two or more hours.",
"      <br/>",
"      <br/>",
"      To calculate the BASDAI score, the sum of the scores for questions one through four is added to the mean of the sum of the scores for questions five and six; the total is divided by five to calculate the disease activity score. A BASDAI score of at least 4.0 (out of a maximum of 10) indicates severe disease activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Functional disability and health related status &mdash; In clinical practice, the particular daily activities and quality of life parameters to be assessed depend upon the judgment of each attending physician. In clinical research on AS, functional disability and health related quality of life are numerically scored using the Bath Ankylosing Spondylitis Functional index (BASFI) and the AS Quality of Life instrument (ASQoL), respectively (",
"      <a class=\"external\" href=\"file://www.asas-group.org/\">",
"       file://www.asas-group.org/",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24895116\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the general physical examination, the physical examination in AS focuses on three areas: axial joints, including the hips; peripheral joints; and entheses. Details of the assessment used in research are available (",
"    <a class=\"external\" href=\"file://www.asas-group.org/\">",
"     file://www.asas-group.org/",
"    </a>",
"    and [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]).The parameters below are those used in clinical practice.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical spine &mdash; AS may cause forward stooping of the thoracic and cervical spine. The degree of flexion deformity is measured by asking the patient to stand erect with heels and buttocks against a wall and to extend his or her neck, while keeping the chin (mandible) horizontal in an attempt to touch the wall. A normal individual can touch the wall with the occiput. The distance between the occiput and the wall in a patient with AS reflects the degree of cervical deformity (",
"      <a class=\"graphic graphic_figure graphicRef62964 \" href=\"UTD.htm?3/22/3439\">",
"       figure 1",
"      </a>",
"      ). In addition, the range of flexion, extension, lateral flexion and rotation are also recorded.",
"     </li>",
"     <li>",
"      Thoracic spine &mdash; The range of motion of the costovertebral joints is measured by the degree of chest expansion. Chest expansion is measured at the level of the fourth intercostal space or just below the breasts in females. The patient is instructed to exert a maximal forced expiration followed by a maximal inspiration. Normal expansion is usually &gt;2.5 cm.",
"     </li>",
"     <li>",
"      Lower spine &mdash; Range of motion of the lower spine is tested in the sagittal plane by the Schober test, and in the coronal plane by the extent of lateral spinal flexion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Schober test &mdash; The Schober test measures the forward flexion of the lumbar spine (",
"      <a class=\"graphic graphic_figure graphicRef58884 \" href=\"UTD.htm?6/39/6768\">",
"       figure 2",
"      </a>",
"      ). The patient stands erect; a mark is placed at the midpoint of a line joining the posterior superior iliac spines (dimples of Venus); another mark is made 10 cm above it in the midline. The patient then bends forward maximally without bending the knees and the distance is measured again. In normal individuals, the difference between the two measurements should exceed 4 cm.",
"     </li>",
"     <li>",
"      Lateral spinal flexion &mdash; With the patient standing erect with heel and back against a wall and knees and hands extended, the distance between the tip of the middle finger and the floor is measured. The patient is then instructed to bend sideways without bending the knees or lifting the heels. A second measurement is made and the difference between the two is recorded. The final result is the averaged measurements of right and left flexion. Normal is greater than 10 cm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hip joint &mdash; Hip involvement should be suspected when a patient shows an abnormal gait. It is verified by testing whether there is limitation of flexion, internal and external rotation, or pain at the extremes of these joint motions. Destructive disease at the hip joints in AS can lead to flexion deformities. However, a unilateral flexion deformity is frequently masked by compensatory motion in the spine. To eliminate this problem during physical examination, the patient is asked to lie supine and maximally flex one hip. If there is a flexion deformity of the contralateral hip, the knee of the contralateral limb will be raised and the degree of flexion deformity can be measured by the angle of the contralateral thigh (",
"      <a class=\"graphic graphic_figure graphicRef64736 graphicRef77527 \" href=\"UTD.htm?0/21/340\">",
"       figure 3A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Peripheral joint count &mdash; This involves a 44 joint count of the number of tender",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      swollen joints, including those of the ankles, feet and the sternoclavicular joints (page II40 in handbook in",
"      <a class=\"external\" href=\"file://www.asas-group.org/\">",
"       file://www.asas-group.org/",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/7\">",
"       7",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Sausage digit (dactylitis) &mdash; The number of digits that have sausage appearance should be determined.",
"     </li>",
"     <li>",
"      Enthesitis count &mdash; At least 18 entheseal sites are assessed during clinical trials (",
"      <a class=\"external\" href=\"file://www.asas-group.org/\">",
"       file://www.asas-group.org/",
"      </a>",
"      ). In practice, the minimum should be at the heel, at the sites where the Achilles tendon and the plantar fascia are each attached to the calcaneus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Assessment by imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In research, radiographic damage of the spine is assessed using lateral views of the cervical and lumbar spine, graded vertebra by vertebra, and scored, for example, using the Modified Stokes Ankylosing Spondylitis Spine Score (mSASSS) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/8\">",
"     8",
"    </a>",
"    ]. In clinical practice, it is useful to examine the anterosuperior and anteroinferior margins of the lumbar vertebrae on a lateral spine radiograph, and to record those with syndesmophytes. In advanced disease, plain radiographs of the spine will reveal \"bamboo spine\" with virtually complete fusion of the vertebral column. At that stage there is usually fusion of the sacroiliac joints (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75935 graphicRef50665 \" href=\"UTD.htm?40/42/41634\">",
"     image 1A-B",
"    </a>",
"    ). Because disease progression is slow, unless changes are suspected, it is not necessary to repeat radiographs of the vertebrae more than once every two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24895270\">",
"    <span class=\"h2\">",
"     Assessment by acute phase reactants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The erythrocyte sedimentation rate (ESR)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C-reactive protein (CRP) are useful for monitoring disease activity, if they are elevated at baseline of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24895277\">",
"    <span class=\"h2\">",
"     Extraarticular involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods of monitoring extraarticular involvement, such as uveitis, are based upon standards used for the organs being involved. AS is associated with increased risk of both osteoporosis and cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Recommendations for office practice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are a suggested set of indicators for minimum evaluation in initial visits and for monitoring disease progression:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient self assessment of pain (1-10)",
"     </li>",
"     <li>",
"      Bath Ankylosing Spondylitis Disease Activity index (BASDAI)",
"     </li>",
"     <li>",
"      Daily activities that are limited by disease",
"     </li>",
"     <li>",
"      Physician's global assessment on a scale of 1 (mild) to 4 (severe)",
"     </li>",
"     <li>",
"      ESR or CRP",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of monitoring depends on the course of symptoms, severity of disease and the therapies being used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most AS patients with mild disease that is restricted to a small area of involvement are able to maintain almost full functional and employment capacity. However, a minority of patients develop severe skeletal restrictions or life-threatening extra-musculoskeletal complications. A questionnaire survey found that employment is affected in approximately 30 percent of the males with AS. However, the majority of patients can work well into their fifties [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disease activity usually fluctuates in the individual patient, with symptoms usually persisting over decades. Approximately 1 percent of patients develops a stage of \"burn-out\" of disease activity and enters long-term remission [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prognostic indicators",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of prognostic indicators were identified before the use of biologics in patients with AS. One study, for example, evaluated 328 patients with spondyloarthritis; seven variables at entry correlated with increased disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hip arthritis &mdash; odds ratio (OR) 23",
"     </li>",
"     <li>",
"      Sausage-like finger or toe &mdash; OR 8",
"     </li>",
"     <li>",
"      Poor efficacy of NSAIDs &mdash; OR 8",
"     </li>",
"     <li>",
"      High erythrocyte sedimentation rate (&gt;30",
"      <span class=\"nowrap\">",
"       mm/h)",
"      </span>",
"      &mdash; OR 7",
"     </li>",
"     <li>",
"      Limitation in range of motion of the lumbar spine &mdash; OR 7",
"     </li>",
"     <li>",
"      Oligoarthritis &mdash; OR 4",
"     </li>",
"     <li>",
"      Onset less than 16 years of age &mdash; OR 3",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A mild outcome was likely if none of these factors was present at entry (sensitivity 93 percent, specificity 78 percent). However, a severe outcome was predictable if the hip were involved or if three factors were present (sensitivity 50 percent), and mild disease could be virtually excluded (specificity 98 percent). Patients with these features should therefore be followed at more frequent intervals.",
"   </p>",
"   <p>",
"    A number of other factors have been associated with a poor outcome in patients with AS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. These include cigarette smoking, increasing severity of radiographic changes, active disease as assessed by a disease activity index, functional impairment as assessed by a self report, lower educational attainment, presence of other diseases related to spondyloarthritis (eg, psoriasis, inflammatory bowel disease), male sex, a history of uveitis, and occupational activities involving either dynamic flexibility (ability to quickly and repeatedly bend, twist, and stretch) or exposure to whole body vibration (such as driving a truck or operating heavy equipment). Other predictors of poor outcome are HLA-B27, age, the presence of enthesitis, poor functional ability, and elevated CRP [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor necrosis factor inhibitors might be more effective in controlling inflammation when used early in the disease course, prior to the development of changes on plain radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/16\">",
"     16",
"    </a>",
"    ]. However, evidence that such therapy will prevent radiographic progression is lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Spinal cord injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AS suffer an increased rate of spinal fractures. In Finland, the incidence of spinal cord injury among those with AS has been estimated to be increased more than 10-fold, compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/17\">",
"     17",
"    </a>",
"    ]. In those with AS, a majority of spinal cord injuries resulted from slips and falls, an event that was rarely the cause of cord damage in those without AS (53 versus 7 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with AS admitted to the hospital for medical care, mortality is about 1.5 times higher than that of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/18\">",
"     18",
"    </a>",
"    ]. Overall, mortality may be modestly increased. This was illustrated in a review of eight studies on mortality in AS that concluded that there was an increase in standardized mortality rates (SMR) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients with AS had SMR ranging from 1.32 to 2.62 [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/19\">",
"     19",
"    </a>",
"    ]. Those patients who died were older, and had a higher ESR and more inflamed peripheral joints when first seen than did surviving patients. Secondary amyloidosis and cardiovascular complications were the major causes of death attributable to AS. There was also an increased frequency of deaths due to accidents and suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to some other chronic rheumatic diseases (eg, rheumatoid arthritis and Sj&ouml;gren's syndrome) the risk of developing lymphoma does not appear to be significantly increased in patients with AS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education, exercise, and medications are all important in the management of ankylosing spondylitis.",
"   </p>",
"   <p>",
"    Patient education and support, in addition to that provided by the patient&rsquo;s physician, is frequently available from support groups such as the",
"   </p>",
"   <p>",
"    Spondylitis Association of America",
"   </p>",
"   <p>",
"    14827 Ventura Blvd. # 222",
"   </p>",
"   <p>",
"    Sherman Oaks, CA 91403",
"   </p>",
"   <p>",
"    Phone: 1-800-777-8189 or 1-818-981-1616",
"   </p>",
"   <p>",
"    Email: info@spondylitis.org or website",
"    <a class=\"external\" href=\"file://www.spondylitis.org/\">",
"     www.spondylitis.org/",
"    </a>",
"   </p>",
"   <p>",
"    Smoking cessation is recommended for everyone who smokes. It is a modifiable risk factor for poor functional outcome in AS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Home exercises are effective, but supervised exercise programs or formal physical therapy can be of greater benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/21\">",
"     21",
"    </a>",
"    ]. Optimally, an initial evaluation and training by a physical therapist should be part of the therapeutic regimen. Exercises include postural training, range of motion stretching, recreational activities, and perhaps hydrotherapy. In addition, pain relief measures such as local heat or cold can be given a trial. At a minimum, patients with AS should participate in an unsupervised home exercise program [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/22\">",
"     22",
"    </a>",
"    ]. Inpatient rehabilitation is rarely needed [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/23\">",
"     23",
"    </a>",
"    ]. Many patients, however, do not exercise on a frequent basis, despite widespread appreciation of the benefits of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An animated demonstration of exercises tailored for ankylosing spondylitis is available on the following website:",
"    <a class=\"external\" href=\"file://www.nass.co.uk/exercise/\">",
"     file://www.nass.co.uk/exercise/",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Guide books, audio and video aids on compact disc and digital video disc are available from the Spondylitis Association of America.",
"   </p>",
"   <p>",
"    Patients who are doing well clinically with pharmacologic treatment will also benefit from education and exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. A randomized trial involving 62 patients clinically stable on anti-TNF therapy showed statistically significant benefit in the Bath Ankylosing Spondylitis Disease Activity index and in spinal range of motion after two and six months from the combination of an intensive rehabilitation exercise treatment program with an educational-behavioral program, compared with the educational-behavioral treatment alone or the results of a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy includes one or more of the following: nonsteroidal antiinflammatory drugs (NSAIDs), analgesics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and anti-TNF agents. Systemic glucocorticoids have a limited role, but intraarticular injections may be helpful to some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs should be the first line of treatment for all symptomatic AS patients, unless contraindicated. In many patients, NSAIDs are the only medications required. About 70 to 80 percent of AS patients report substantial relief of their symptoms, including back pain and stiffness, with NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/29\">",
"     29",
"    </a>",
"    ]. This is significantly more than the 15 percent observed in mechanical low back pain. NSAID use also results in decreased pain in peripheral joints [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/30\">",
"     30",
"    </a>",
"    ]. There are two issues related to NSAID therapy in AS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The choice of NSAID, including the possible role of selective COX-2 inhibitors &mdash; Initial anecdotal evidence suggested that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      is the most effective NSAID [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/31\">",
"       31",
"      </a>",
"      ]. However, multiple studies support the view that other NSAIDs are also effective [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/32\">",
"       32",
"      </a>",
"      ]. Regardless of the NSAID used, the maximum dose is usually required. To assess the usefulness of a particular NSAID, it should be given at a sustained dose on a regular basis for at least four weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"       \"Nonselective NSAIDs: Overview of adverse effects\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Short-term studies indicate that selective COX-2 inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      and etoricoxib, are as effective as nonselective NSAIDs [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/33-36\">",
"       33-36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"       \"Overview of selective COX-2 inhibitors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"       \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10375?source=see_link\">",
"       \"COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Continuous versus on-demand therapy &mdash;AS patients who have persistent, active, symptomatic disease should use continuous NSAIDs to control symptoms. This approach is in agreement with the 2010",
"      <span class=\"nowrap\">",
"       ASAS/EULAR",
"      </span>",
"      recommendations [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. In addition, a randomized trial and several additional studies have shown that patients who use either continuous daily NSAIDs or high-dose NSAIDs regardless of symptoms may have a lower rate of radiographic progression in the spine [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/37-40\">",
"       37-40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      As an example, in one trial involving 215 patients, which suggested that continuous daily use of NSAIDs may suppress radiographic progression, patients were randomly assigned to receive either continuous or on-demand NSAID therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/37\">",
"       37",
"      </a>",
"      ]. At two years, the degree of radiographic progression was statistically significantly less (by 73 percent) in the patients who were treated continuously with NSAIDs. Patients with more active inflammation seem to particularly benefit from continuous NSAID therapy. In one study, continuous NSAID therapy was especially effective in patients with an elevated erythrocyte sedimentation rate (ESR) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/39\">",
"       39",
"      </a>",
"      ]. In another study, continuous NSAIDs were most effective in patients with high C-reactive protein (CRP) and with the presence of syndesmophytes at baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/40\">",
"       40",
"      </a>",
"      ]. However, the exact clinical meaning of these findings remains to be determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24895494\">",
"    <span class=\"h2\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analgesics and opioids, when used alone, are seldom effective during active AS. However, they can be considered for residual pain, or when NSAIDs are contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Tumor necrosis factor alpha antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-TNF-alpha agents approved in the United States and Europe for use in AS are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    . Concomitant use of an immunomodulatory drug, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is not required, as this provides no additional benefit but may increase the cost and the risk of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Overall efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2007 meta-analysis indicated that all three of the anti-TNF alpha agents then available (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ) were similar in efficacy in patients with AS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/42\">",
"     42",
"    </a>",
"    ]. These medications have not been compared directly with each other, but indirect comparisons were unable to distinguish significant differences. At week 12 of trials, patients treated with the anti-TNF agents were 3.6-fold more likely, compared with those treated with placebo, to achieve 50 percent improvement (using a composite measure, the ASAS50). Approximately 80 percent of patients with AS respond to treatment with one of these agents and approximately one half get at least 50 percent improvement in a composite index, such as that adopted by the Ankylosing Spondylitis Assessment Group that includes [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient global assessment",
"     </li>",
"     <li>",
"      Patient assessment of pain",
"     </li>",
"     <li>",
"      A functional assessment, such as ability to carry out certain activities with which the patient had difficulty prior to treatment",
"     </li>",
"     <li>",
"      Degree of inflammation as assessed by morning stiffness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The responses are typically rapid. Eighty percent of patients who experienced a &gt;50 percent response by 12 weeks did so within the first six weeks of treatment. The long-term effects of anti-TNF therapy appear to be durable, with continued efficacy for at least two years in two observational studies, and for five years in a third study [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Patients who do not respond to or do not tolerate one anti-TNF agent may respond to an alternate anti-TNF agent [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of anti-TNF therapy may also decrease the frequency of recurrences of uveitis in patients with AS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite their efficacy, the indiscriminate use of anti-TNF-alpha drugs is discouraged because of cost concerns and a lack of long-term safety data [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/49\">",
"     49",
"    </a>",
"    ]. A guideline for selecting patients for whom anti-TNF therapy is indicated, dosing (amount and frequency), and monitoring for efficacy and adverse effects has been developed and updated by an international panel of physicians with expertise in the treatment of AS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. A summary of guidelines is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17782?source=see_link\">",
"     \"General guidelines for use of anti-tumor necrosis factor alpha agents in ankylosing spondylitis and axial spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15027495\">",
"    <span class=\"h3\">",
"     Use of TNF antagonists in early and advanced axial spondyloarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies of anti-tumor necrosis factor (TNF) therapy have recruited patients whose states of disease are neither very early nor very advanced. However, in trials that have evaluated these populations, the highest remission rates are observed with patients with very early disease [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/53\">",
"     53",
"    </a>",
"    ], and patients with advanced disease have also benefited from anti-TNF therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Predictors of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following parameters are possible predictors of a good response to TNF antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Shorter disease duration, which is the best predictor",
"     </li>",
"     <li>",
"      Elevated CRP",
"     </li>",
"     <li>",
"      Young age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Improvement of greater than 50 percent may be seen in up to 80 percent of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15027527\">",
"    <span class=\"h3\">",
"     Switching to a second TNF antagonist",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large open label study addressed the effectiveness of switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    when patients failed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    because of either an inadequate response or adverse effect. Such patients were compared with those begun on adalimumab who had never received etanercept or infliximab. After 12 weeks, a BASDAI50 response was observed in 63 percent of patients who had never received TNF antagonists, and 40.8 percent of patients who had been treated with prior TNF antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/57\">",
"     57",
"    </a>",
"    ]. In general, switching to another TNF antagonist is more useful for patients who have loss of response to the first one.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15027553\">",
"    <span class=\"h3\">",
"     Stopping TNF antagonists when patients have obtained a major clinical response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients will relapse soon after discontinuing the TNF antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/16\">",
"     16",
"    </a>",
"    ]. It is possible that the dose or interval of treatment can be modified, but this has not been systematically studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15027594\">",
"    <span class=\"h3\">",
"     Improvement in bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that use of anti-TNF biologic agents may be associated with improved bone density. Three studies utilizing anti-TNF biologic agents in the treatment of 75 patients with various forms of spondyloarthritis were reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/58\">",
"     58",
"    </a>",
"    ]; when the changes in bone density from baseline to the end of observation were compared, patients receiving anti-TNF agents had increases in bone mineral density of 3.2 to 3.6 percent at the lumbar spine and 1.8 to 2.0 percent at the hip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     General side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of these agents when used to treat rheumatic disease are discussed separately. Potential adverse effects such as an increased risk of reactivation of latent tuberculosis and the exacerbation or development of demyelinating disease must be considered when using these agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'TNF inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    , when used in patients with AS, has been temporally associated with the development of palmoplantar pustulosis [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link&amp;anchor=H25#H25\">",
"     \"Neutrophilic dermatoses\", section on 'Palmoplantar pustulosis'",
"    </a>",
"    .) Three cases of retropharyngeal abscess were also noted among 107 patients with a variety of spondyloarthritis (incidence of 1.6 per 100 patient years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant benefit has been noted in patients with axial as well as peripheral spondyloarthritis using the chimeric mouse-human monoclonal anti-TNF alpha antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/59-64\">",
"     59-64",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    use also resulted in improvement in the synovial histopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/65\">",
"     65",
"    </a>",
"    ]. Decreases in vascularity, thickness of the lining layer, and the degree of infiltration of synovium by neutrophils, and T cells were seen, and have been confirmed in a subsequent study in two additional cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study of this anti-TNF agent randomly assigned 357 North American and European patients to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at week 0, 2, 6, 12, and 16) or placebo (The ASSERT trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients with complete spinal ankylosis were excluded from this study, as were those with a recent infection, active or latent tuberculosis, or immunosuppression due to",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    or solid organ transplantation. Patients with other diseases that could be exacerbated by infliximab, including demyelinating disorders and heart failure, were also excluded.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    and other DMARDs were prohibited. The primary outcome assessed at 24 weeks was a change that met ASAS criteria for a 20 percent improvement (ASAS20).",
"   </p>",
"   <p>",
"    This and other controlled trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    utilized a 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], which is higher than the usual dose of 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for patients with rheumatoid arthritis. The 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose appears to remain effective when used for periods of at least three years [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/46,70,71\">",
"     46,70,71",
"    </a>",
"    ]. Whether a lower dose would be equally effective is uncertain. When 21 patients were given the 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose in one of the observational studies cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/63\">",
"     63",
"    </a>",
"    ], infliximab appeared to be effective; however, three patients were given the 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose after three months of therapy because of inadequate control of symptoms on the lower dose. Some patients who are not controlled with infusions every eight weeks may benefit from a reduced interval between treatments (eg, six weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The time to maximal response may be as long as six weeks, some patients experience pain relief shortly after the first infusion. Our experience suggests that patients with longstanding disease are less likely to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    therapy.",
"   </p>",
"   <p>",
"    Most initial studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    in AS were carried out with patients who had definite sacroiliitis by plain radiography. A recent placebo-controlled study was carried out in a group of patients in whom the majority did not have plain radiographic sacroiliitis. These were inflammatory back pain patients with positive MRI changes of sacroiliitis and positive testing for HLA-B27. Infliximab was also effective in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case report,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    was effective in reversing symptoms of cauda equina syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/74\">",
"     74",
"    </a>",
"    ]. No other interventions have previously been of benefit, but the utility of this approach in other patients has not yet been demonstrated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    , although routinely used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    to treat rheumatoid arthritis, has not been found to be necessary or provide additional beneficial when infliximab is being used to treat AS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/75\">",
"     75",
"    </a>",
"    ]. The importance of coadministration of MTX on efficacy has not been studied with other TNF-alpha antagonists in AS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several open studies and randomized trials have demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    in AS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/76-81\">",
"     76-81",
"    </a>",
"    ]. Limited data suggest that the symptomatic benefits of etanercept are quickly lost after cessation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , etanercept use also resulted in improvement in synovial pathology in the peripheral joints [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest trial confirmed the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ; it was a well designed, international trial that randomly assigned 277 patients to receive etanercept (25 mg sc twice weekly) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/79\">",
"     79",
"    </a>",
"    ]. After 12 weeks of treatment, the proportion of patients achieving improvements of 20 percent, 50 percent or 70 percent were about 60 percent, 45 percent and 25 percent, respectively. Seventeen percent of patients achieved partial remission. These were significantly higher than the corresponding placebo values. In a subset of 40 subjects who had serial MRI examinations of the spine, there was a mean 54 percent decrease in T2-weighted signal in those treated with etanercept, suggesting decreased spinal inflammation, while the placebo group had a slight worsening (increase of 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/85\">",
"     85",
"    </a>",
"    ]. Significant improvement was also noted in spinal and chest wall mobility. Hence, these are also useful follow up parameters for patients receiving anti-TNF therapies. Only injection site reactions were more frequent in the etanercept group. In an unblinded extension of this study, beneficial effects were sustained during nearly two years of continued etanercept treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further support for the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    in AS was provided by a multicenter randomized trial carried out at 14 European sites; 84 ankylosing spondylitis patients were randomly assigned to etanercept (25 mg SC twice a week) or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/80\">",
"     80",
"    </a>",
"    ]. Significant improvement was observed in the etanercept group by week 2, and significantly more patients achieved an ASAS50 at week 12 (48.9 versus 10.3 percent).",
"   </p>",
"   <p>",
"    The results of the multiple randomized trials summarized above show convincingly that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    is effective for patients with ankylosing spondylitis. Weekly dosing with 50 mg appears to result in similar efficacy to 25 mg twice weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    , a humanized anti-TNF monoclonal antibody, is also far more efficacious than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/53,89,90\">",
"     53,89,90",
"    </a>",
"    ]. This was illustrated in a study that randomly assigned 315 patients in a 2:1 ratio to adalimumab (40 mg every other week by subcutaneous injection) or placebo injections [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/89\">",
"     89",
"    </a>",
"    ]. The study population was predominantly Caucasian, male, and HLA-B27 positive with a mean duration of disease of 10 years. A significantly greater proportion of adalimumab-treated patients achieved the primary efficacy endpoint, an ASAS20 response at the end of 12 weeks (58 versus 21 percent). Patients who did not achieve an ASAS20 after 12 weeks were eligible to receive 40 mg weekly. At week 24 all patients were switched to or continued adalimumab 40 mg every other week in an open-label extension of the trial [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/45\">",
"     45",
"    </a>",
"    ]. Of 61 patients treated weekly, ASAS20 responses were achieved after six weeks and after one year by 23 and 34 percent, respectively. At week 24 patients were switched to or continued adalimumab 40 mg every other week in an open-label extension of the trial [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/45\">",
"     45",
"    </a>",
"    ]. At two years, for patients who were still receiving adalimumab, an ASAS20 was achieved by 64.5 percent. The proportion of these patients who experienced over 50 percent improvement in the BASDAI was 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the advantage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    treatment was maintained for up to 24 weeks in the randomized phase of the study, and subsequently maintained for up to two years of follow-up in the open-label phase of the study.",
"   </p>",
"   <p>",
"    At two years, the frequency of patients with serious adverse events that were possibly drug-related was 5.5 percent. No cases of tuberculosis, heart failure, lupus-like symptoms, or demyelinating disease were reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Golimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    is a human anti-TNF alpha monoclonal antibody that is administered by subcutaneous injections once every four weeks. Efficacy for patients with AS appears similar to that of other anti-TNF agents. This was illustrated in a study that randomly assigned 356 patients to golimumab 50 mg, 100 mg or placebo injections every four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/91\">",
"     91",
"    </a>",
"    ]. After 14 weeks ASAS20 responses occurred in 59, 60, and 22 percent of patients in the three groups, respectively. These responses appear to be comparable to those of other TNF antagonists. The recommended dose is 50 mg subcutaneously every four weeks. The precautions and possible side effects are the same as those for the other FDA-approved TNF antagonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Can TNF antagonists halt progression of AS?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although use of these biologic agents has drastically improved the well being of many patients, many unanswered questions remain, including why some patients do not respond to these interventions. The other major question is whether they can halt the radiographic progression of the disease. So far, in comparison to cohorts followed longitudinally prior to the introduction of TNF antagonists, there is no convincing evidence that TNF antagonists can halt the radiological progression of AS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/92\">",
"     92",
"    </a>",
"    ]. From results with animal models, inflammation and bone remodeling are probably two independent processes, and only inflammation may be controlled by anti-TNF agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24895511\">",
"    <span class=\"h2\">",
"     Disease modifying agents (DMARDs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only DMARD regarded as potentially useful in AS is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Sulfasalazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    in patients with peripheral arthritis, such as those with oligoarthritis of the knees",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ankles, for whom a drug other than an anti-TNF agent is desirable, and prefer it to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in this setting. We discontinue sulfasalazine if there is no improvement after a four- to six-month trial at maximum dose. We also consider stopping the agent after a remission has been obtained, with its reinstitution in those who relapse. We do not recommend using sulfasalazine in those with only symptoms or signs of axial disease.",
"   </p>",
"   <p>",
"    A 2006 meta-analysis that included data from 11 randomized clinical trials of SSZ concluded that it was significantly more effective than placebo in reducing spinal stiffness and in lowering the ESR [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/93\">",
"     93",
"    </a>",
"    ]. However, most of the clinical trials of SSZ have been relatively small. Two of the larger trials involved 89 and 264 patients with AS, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. In both of these trials, SSZ was more effective for the treatment of peripheral arthritis than for axial disease.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ) has declined very considerably since the introduction of the TNF antagonists, which are more effective for both axial and peripheral disease [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Most experts in the care of patients with spondyloarthropathy recommend SSZ only for AS patients with peripheral arthritis, and many experts do not recommend its use if TNF antagonists are available [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/52\">",
"     52",
"    </a>",
"    ]. In one study, SSZ was less effective in reducing disease activity, compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , whether or not peripheral joint involvement was present [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A typical dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    used in clinical trials was one 500 mg tablet daily for the first week, increasing by one tablet per day each subsequent week to a total of four to six tablets daily, divided and given twice a day. For those on the higher daily dose, the dose was reduced to four tablets if the higher dose was not tolerated. Approximately 60 percent of the sulfasalazine-treated patients reported side effects, all reversible on withdrawal of the drug. The most common side effects were nausea, dizziness, headache, and rash.",
"   </p>",
"   <p>",
"    There is no guideline as to how patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    should be monitored for side effects. Leukopenia and neutropenia can develop quite suddenly, with an incidence varying from 1 to 5 percent. We recommend that blood counts be monitored at least every three months, and more frequently in the initial period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=see_link\">",
"     \"Sulfasalazine in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6377225\">",
"    <span class=\"h3\">",
"     Other DMARDs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      &mdash; Some studies have suggested that methotrexate may be effective in some patients with AS [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/99,100\">",
"       99,100",
"      </a>",
"      ]. However, a 2006 meta-analysis of the efficacy of methotrexate in AS found no evidence of benefit in this disease [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/101\">",
"       101",
"      </a>",
"      ]. Additionally, the combination of methotrexate and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      did not increase the efficacy or decrease the risk of adverse effects compared with infliximab alone [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/75,102,103\">",
"       75,102,103",
"      </a>",
"      ]. Thus, there is currently a lack of evidence to support the use of methotrexate in the treatment of AS. Nevertheless, some rheumatologists do prescribe methotrexate for AS patients with peripheral arthritis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       Leflunomide",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; Limited data suggest that leflunomide is of little or no benefit for patients with AS [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/104,105\">",
"       104,105",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of systemic glucocorticoids in AS has not been assessed in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/106\">",
"     106",
"    </a>",
"    ]. These patients already have significant loss of bone density, which can be exacerbated by steroid therapy. We suggest not using systemic glucocorticoids on a long-term basis for patients with AS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraarticular injections, although never evaluated in a well designed clinical trial to our knowledge, and local injections into painful plantar fasciae can be helpful for peripheral arthritis and plantar fasciitis, respectively. Local injections into the area of Achilles tendon are not recommended as rupture of the tendon may follow glucocorticoid infiltration at this site.",
"   </p>",
"   <p>",
"    Injection of long-acting glucocorticoids into the sacroiliac joints may be beneficial in patients who complain of marked pain at the sacroiliac joints that is unresponsive to systemic medications. Benefit of injection of long-acting glucocorticoid has been found in some but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. A double-blind study reported more than 70 percent relief in over 80 percent of injected sacroiliac joints [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/108\">",
"     108",
"    </a>",
"    ]. Relief persisted for as long as six months or more after the injection and no complications were seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       Pamidronate",
"      </a>",
"      &mdash; Pamidronate, a bisphosphonate, has been evaluated in the treatment of AS, because of some evidence of antiinflammatory activity and its effect on bone turnover [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/109-112\">",
"       109-112",
"      </a>",
"      ]. Dose-dependent benefit of pamidronate treatment was demonstrated in a trial involving 84 patients with AS with a suboptimal response to NSAID therapy who were randomly assigned to one of two doses of pamidronate (60",
"      <span class=\"nowrap\">",
"       mg/month",
"      </span>",
"      or 10",
"      <span class=\"nowrap\">",
"       mg/month),",
"      </span>",
"      administered intravenously for six months [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/110\">",
"       110",
"      </a>",
"      ]. Other observational studies have reported modest clinical benefit with pamidronate (60",
"      <span class=\"nowrap\">",
"       mg/month),",
"      </span>",
"      but several patients have experienced serious adverse effects with this regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/111-113\">",
"       111-113",
"      </a>",
"      ]. Additional data from randomized trials would be required before pamidronate could be considered for use in routine clinical practice for the treatment of AS.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      &mdash; The potential benefit of thalidomide has been examined in AS because of its immunomodulatory properties, including its effects on tumor necrosis factor (TNF) [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/114-116\">",
"       114-116",
"      </a>",
"      ]. A 2002 review of observational studies reported that among more than 50 patients treated with thalidomide, 68 percent improved and 19 percent withdrew from treatment due to lack of efficacy or adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/116\">",
"       116",
"      </a>",
"      ]. As an example, thalidomide (300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for one month, followed by 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      thereafter) was beneficial in two patients with refractory AS, prior to the availability of biologic anti-TNF therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/114\">",
"       114",
"      </a>",
"      ]. In the author's experience, the maximum response is relatively slow, being observed 6 to 12 months after initiation of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/115\">",
"       115",
"      </a>",
"      ]. Randomized trials are needed to better define the role of thalidomide in the treatment of AS, and the seriousness of the potential side effects will need to be considered in determining whether it has a role in therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      &mdash; Rituximab, a monoclonal antibody that depletes B cells, has undergone preliminary study in 20 patients with active AS, based in part upon previous findings of dense B cell infiltration in subchondral bone of inflamed sacroiliac joints of patients with AS [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/117\">",
"       117",
"      </a>",
"      ]. Significant efficacy at week 24 following initial intravenous administration of rituximab was observed in patients who were naive to tumor necrosis factor (TNF) inhibitor therapy, but not in those who had already failed to respond to a TNF inhibitor (ASAS20 response 50 versus 30 percent, BASDAI50 response 50 versus 0 percent). Further study, including randomized trials, will be required to determine whether there is a role for rituximab in the treatment of AS.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"       Abatacept",
"      </a>",
"      &mdash; Abatacept, a biologic agent which blocks T cell costimulation, has not been found to be useful in AS, despite its activity as a disease-modifying antirheumatic drug in patients with rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other biologic agents &mdash; Inhibitors of interleukin (IL)-6,",
"      <span class=\"nowrap\">",
"       IL-12/23,",
"      </span>",
"      and IL-17A have been the subject of investigation, but there is presently a lack of evidence for the use in AS of any biologics other than the TNF antagonists [",
"      <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/1,119,120\">",
"       1,119,120",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hip and spine surgery may be beneficial in selected patients with AS. Physicians and anesthetists should be cautioned that such patients may have reduced chest expansion and more rigid cervical spines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Total hip arthroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total hip arthroplasty (THA, total hip replacement) is indicated in AS whenever there is severe, persistent pain or severe limitation in mobility and quality of life due to hip involvement. THA is more common in patients with early onset of disease, axial, and entheseal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/121\">",
"     121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=see_link\">",
"     \"Total hip arthroplasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there has been concern that patients with AS undergoing THA at a young, active age will experience a higher incidence of replacement failure compared with older, less active patients, excellent long term results were found in a group of 340 patients with AS who had undergone initial THA at a mean age of 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/122\">",
"     122",
"    </a>",
"    ]. The proportions of such hips that did not require revision at 10, 15, and 20 years following operation were 90, 78, and 64 percent, respectively. In another analysis of 181 hips, the survival of the prosthetic joint was 71 percent at 27 years [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/123\">",
"     123",
"    </a>",
"    ]. Currently, the",
"    <span class=\"nowrap\">",
"     ASAS/EULAR",
"    </span>",
"    recommendations are that age not be a factor in decisions regarding THA.",
"   </p>",
"   <p>",
"    Patients with AS may be at higher risk of developing heterotopic ossification following joint replacement, but this remains an unusual complication [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/124\">",
"     124",
"    </a>",
"    ]. If, however, this complication has occurred following a prior joint arthroplasty, prophylactic therapy has been recommended, such as a nonsteroidal antiinflammatory drug beginning on the day of surgery or radiation therapy (preoperative or postoperative). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=see_link&amp;anchor=H38#H38\">",
"     \"Complications of total hip arthroplasty\", section on 'Heterotopic ossification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Spinal surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical fusion is indicated for the very small number of patients who develop atlantoaxial subluxation with impairment in neurologic function. This problem is managed in a fashion similar to that in rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"     \"Cervical subluxation in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Wedge osteotomy is indicated in those patients who develop flexion deformities severe enough to impair the ability to look in a forward direction.",
"   </p>",
"   <p>",
"    Spinal surgeons should be consulted in the event of acute vertebral fractures, which should be suspected in patients who develop unusual neck or back pain, even in the absence of trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\", section on 'Fracture of ankylosed spine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=see_link\">",
"       \"Patient information: Ankylosing spondylitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"       \"Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We concur with treatment guidelines formulated by an international working group of experts in the treatment of AS [",
"    <a class=\"abstract\" href=\"UTD.htm?34/23/35194/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The grading of evidence in the summary and recommendations that follow is assigned by the authors and editors of this UpToDate topic review, and differs slightly from that in the",
"    <span class=\"nowrap\">",
"     ASAS/EULAR",
"    </span>",
"    recommendations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of patients with AS must be individualized. The level of disease activity, presence of poor prognostic factors or concomitant illnesses, degree of functional impairment, patient's tolerance of the risk of adverse effects, expectations of treatment, and other psychosocial factors must be considered. The level of disease activity can be scored by using the BASDAI questionnaire. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Assessment and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend use of an NSAID as initial therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Any NSAID may be effective. Regular use for a period of four weeks allows the maximal effect of a given NSAID to be assessed. If some, but not satisfactory improvement is noted, the NSAID may be continued indefinitely while other interventions (see below) are initiated. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Nonsteroidal antiinflammatory drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The NSAID can be supplemented by use of an analgesic; occasionally, low potency opioids may be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend an exercise program for all patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Individual physical therapy may be needed by some. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Nonpharmacological treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT using systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest intraarticular glucocorticoids for persistent peripheral joint involvement, enthesitis at sites other than the Achilles tendon, and for pain of sacroiliitis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traditional nonbiologic DMARDs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      ) are ineffective for those with axial disease. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Tumor necrosis factor alpha antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with axial disease who do not respond to NSAIDs we recommend an anti-TNF agent (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If there is failure to one anti-TNF agent, it is possible that an alternate anti-TNF agent can be effective. Prior to initiating anti-TNF therapy, active infection and latent tuberculosis should be excluded. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Tumor necrosis factor alpha antagonists'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"       \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"       \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with predominantly peripheral arthritis who do not respond adequately to NSAIDs and for whom a TNF inhibitor is unavailable or is contraindicated, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , unless there are contraindications (eg, allergy to sulfonamide antibiotics) to this drug (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Sulfasalazine'",
"      </a>",
"      above.)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      is being used by some clinicians as an alternative. (See",
"      <a class=\"local\" href=\"#H6377225\">",
"       'Other DMARDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a paucity of data to guide therapy if the treatments recommended above are ineffective or contraindicated. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical interventions are used selectively. Total joint replacement may be necessary for those whose joints are already destroyed. Wedge osteotomy of the spine is reserved for those patients with severe spinal deformities, as in patients with neck flexion so pronounced that useful forward vision is difficult or impossible. Fusion of the atlantoaxial joint of the cervical spine is needed if there is significant neck or occipital pain or evidence of neurologic dysfunction due to C1-C2 (atlantoaxial) subluxation, as occurs in patients with rheumatoid arthritis. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"       \"Cervical subluxation in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/1\">",
"      Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/2\">",
"      Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/3\">",
"      Jang JH, Green CE, Assassi S, et al. The contribution of disease activity on functional limitations over time through psychological mediators: a 12-month longitudinal study in patients with ankylosing spondylitis. Rheumatology (Oxford) 2011; 50:2087.",
"     </a>",
"    </li>",
"    <li>",
"     Spondyloarthritis research and treatment network. www.spartangroup.org (Accessed on August 11, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/5\">",
"      Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 2007; 34:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/6\">",
"      Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007; 34:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/7\">",
"      Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/8\">",
"      Wanders A, Landew&eacute; R, Spoorenberg A, et al. Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order. Ann Rheum Dis 2004; 63:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/9\">",
"      Koh WH, Jones SD, Garrett Sl, et al. Risks and determinants of unemployment in ankylosing spondylitis (abstract). Arthritis Rheum 1994; 37:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/10\">",
"      Kennedy LG, Edmunds L, Calin A. The natural history of ankylosing spondylitis. Does it burn out? J Rheumatol 1993; 20:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/11\">",
"      Amor B, Santos RS, Nahal R, et al. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994; 21:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/12\">",
"      Doran MF, Brophy S, MacKay K, et al. Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 2003; 30:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/13\">",
"      Pradeep DJ, Keat A, Gaffney K. Predicting outcome in ankylosing spondylitis. Rheumatology (Oxford) 2008; 47:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/14\">",
"      Ward MM, Reveille JD, Learch TJ, et al. Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis Rheum 2008; 59:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/15\">",
"      Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011; 70:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/16\">",
"      Haibel H, Sieper J. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker? Curr Opin Rheumatol 2010; 22:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/17\">",
"      Alaranta H, Luoto S, Konttinen YT. Traumatic spinal cord injury as a complication to ankylosing spondylitis. An extended report. Clin Exp Rheumatol 2002; 20:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/18\">",
"      Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993; 52:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/19\">",
"      Zochling J, Braun J. Mortality in ankylosing spondylitis. Clin Exp Rheumatol 2008; 26:S80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/20\">",
"      Askling J, Klareskog L, Blomqvist P, et al. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006; 65:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/21\">",
"      Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008; :CD002822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/22\">",
"      Elyan M, Khan MA. Does physical therapy still have a place in the treatment of ankylosing spondylitis? Curr Opin Rheumatol 2008; 20:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/23\">",
"      Lubrano E, D'Angelo S, Parsons WJ, et al. Effectiveness of rehabilitation in active ankylosing spondylitis assessed by the ASAS response criteria. Rheumatology (Oxford) 2007; 46:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/24\">",
"      Passalent LA, Soever LJ, O'Shea FD, Inman RD. Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol 2010; 37:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/25\">",
"      Masiero S, Bonaldo L, Pigatto M, et al. Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol 2011; 38:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/26\">",
"      Spadaro A, De Luca T, Massimiani MP, et al. Occupational therapy in ankylosing spondylitis: Short-term prospective study in patients treated with anti-TNF-alpha drugs. Joint Bone Spine 2008; 75:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/27\">",
"      Dubey SG, Leeder J, Gaffney K. Physical therapy in anti-TNF treated patients with ankylosing spondylitis. Rheumatology (Oxford) 2008; 47:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/28\">",
"      Lubrano E, D'Angelo S, Spadaro A, et al. Rehabilitation for ankylosing spondylitis in the era of biologics: any room left for this treatment? J Rheumatol 2011; 38:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/29\">",
"      Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 2008; 58:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/30\">",
"      Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006; 65:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/31\">",
"      Calin A, Elswood J. A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. J Rheumatol 1990; 17:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/32\">",
"      Sidiropoulos PI, Hatemi G, Song IH, et al. Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatology (Oxford) 2008; 47:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/33\">",
"      van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/34\">",
"      Barkhuizen A, Steinfeld S, Robbins J, et al. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 2006; 33:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/35\">",
"      Dougados M, B&eacute;hier JM, Jolchine I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/36\">",
"      Sieper J, Klopsch T, Richter M, et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 2008; 67:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/37\">",
"      Wanders A, Heijde Dv, Landew&eacute; R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/38\">",
"      Haroon N, Kim TH, Inman RD. NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Ann Rheum Dis 2012; 71:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/39\">",
"      Kroon F, Landew&eacute; R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012; 71:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/40\">",
"      Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012; 71:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/41\">",
"      Sieper J. Developments in the scientific and clinical understanding of the spondyloarthritides. Arthritis Res Ther 2009; 11:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/42\">",
"      McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/43\">",
"      Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/44\">",
"      Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005; 53:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/45\">",
"      van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009; 68:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/46\">",
"      Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008; 67:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/47\">",
"      Cantini F, Niccoli L, Benucci M, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006; 55:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/48\">",
"      Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/49\">",
"      Jois RN, Gaffney K, Keat A. Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues. Rheumatology (Oxford) 2007; 46:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/50\">",
"      Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/51\">",
"      Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/52\">",
"      van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/53\">",
"      Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/54\">",
"      Dougados M, Braun J, Szanto S, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 2011; 70:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/55\">",
"      Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/56\">",
"      Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009; 36:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/57\">",
"      Rudwaleit M, Van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010; 12:R117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/58\">",
"      Barnabe C, Hanley DA. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin Arthritis Rheum 2009; 39:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/59\">",
"      Baeten D, Kruithof E, Van den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/60\">",
"      Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/61\">",
"      Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/62\">",
"      Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001; 28:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/63\">",
"      Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002; 29:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/64\">",
"      Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003; 62:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/65\">",
"      Baeten D, Kruithof E, Van den Bosch F, et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001; 44:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/66\">",
"      Kruithof E, Baeten D, Van den Bosch F, et al. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 2005; 64:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/67\">",
"      van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/68\">",
"      Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/69\">",
"      Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/70\">",
"      Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005; 64:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/71\">",
"      Sieper J, Baraliakos X, Listing J, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 2005; 44:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/72\">",
"      Collantes-Estevez E, Mu&ntilde;oz-Villanueva MC, Zarco P, et al. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. Rheumatology (Oxford) 2005; 44:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/73\">",
"      Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009; 60:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/74\">",
"      Cornec D, Devauchelle Pensec V, Joulin SJ, Saraux A. Dramatic efficacy of infliximab in cauda equina syndrome complicating ankylosing spondylitis. Arthritis Rheum 2009; 60:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/75\">",
"      Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008; 58:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/76\">",
"      Barthel HR. Rapid remission of treatment-resistant ankylosing spondylitis with etanercept--a drug for refractory ankylosing spondylitis? Arthritis Rheum 2001; 45:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/77\">",
"      Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001; 44:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/78\">",
"      Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/79\">",
"      Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48:3230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/80\">",
"      Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/81\">",
"      Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011; 70:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/82\">",
"      Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/83\">",
"      Rudwaleit M, Baraliakos X, Listing J, et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005; 64:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/84\">",
"      Kruithof E, De Rycke L, Roth J, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005; 52:3898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/85\">",
"      Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005; 52:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/86\">",
"      Davis JC Jr, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008; 67:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/87\">",
"      van der Heijde D, Da Silva JC, Dougados M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/88\">",
"      Braun J, McHugh N, Singh A, et al. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 2007; 46:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/89\">",
"      van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/90\">",
"      Lambert RG, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2007; 56:4005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/91\">",
"      Inman RD, Davis JC Jr, Heijde Dv, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/92\">",
"      van der Heijde D, Landew&eacute; R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/93\">",
"      Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006; 33:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/94\">",
"      Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/95\">",
"      Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/96\">",
"      Ward MM. Sulfasalazine for the treatment of ankylosing spondylitis: relic or niche medication? Arthritis Rheum 2011; 63:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/97\">",
"      Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011; 63:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/98\">",
"      Braun J, Pavelka K, Ramos-Remus C, et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol 2012; 39:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/99\">",
"      Sampaio-Barros PD, Costallat LT, Bertolo MB, et al. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000; 29:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/100\">",
"      Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, et al. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/101\">",
"      Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006; :CD004524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/102\">",
"      Marzo-Ortega H, McGonagle D, Jarrett S, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005; 64:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/103\">",
"      Li EK, Griffith JF, Lee VW, et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 2008; 47:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/104\">",
"      van Denderen JC, van der Paardt M, Nurmohamed MT, et al. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005; 64:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/105\">",
"      Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/106\">",
"      Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res 2002; 4:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/107\">",
"      Hanly JG, Mitchell M, MacMillan L, et al. Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondyloarthropathy: results of a 6 month controlled study. J Rheumatol 2000; 27:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/108\">",
"      Maugars Y, Mathis C, Berthelot JM, et al. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol 1996; 35:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/109\">",
"      Maksymowych WP, Lambert R, Jhangri GS, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001; 28:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/110\">",
"      Maksymowych WP, Jhangri GS, Fitzgerald AA, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/111\">",
"      Cairns AP, Wright SA, Taggart AJ, et al. An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 2005; 64:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/112\">",
"      Grover R, Shankar S, Aneja R, et al. Treatment of ankylosing spondylitis with pamidronate: an open label study. Ann Rheum Dis 2006; 65:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/113\">",
"      Toussirot E, Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol 2007; 19:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/114\">",
"      Breban M, Gombert B, Amor B, Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 1999; 42:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/115\">",
"      Huang F, Gu J, Zhao W, et al. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 2002; 47:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/116\">",
"      Huang F, Wei JC, Breban M. Thalidomide in ankylosing spondylitis. Clin Exp Rheumatol 2002; 20:S158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/117\">",
"      Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010; 62:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/118\">",
"      Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011; 70:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/119\">",
"      Song IH, Poddubnyy D. New treatment targets in ankylosing spondylitis and other spondyloarthritides. Curr Opin Rheumatol 2011; 23:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/120\">",
"      Kiltz U, Heldmann F, Baraliakos X, Braun J. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr Opin Rheumatol 2012; 24:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/121\">",
"      Vander Cruyssen B, Mu&ntilde;oz-Gomariz E, Font P, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford) 2010; 49:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/122\">",
"      Sweeney S, Gupta R, Taylor G, Calin A. Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol 2001; 28:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/123\">",
"      Joshi AB, Markovic L, Hardinge K, Murphy JC. Total hip arthroplasty in ankylosing spondylitis: an analysis of 181 hips. J Arthroplasty 2002; 17:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?34/23/35194/abstract/124\">",
"      Nilsson OS, Persson PE. Heterotopic bone formation after joint replacement. Curr Opin Rheumatol 1999; 11:127.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7790 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35194=[""].join("\n");
var outline_f34_23_35194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSESSMENT AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24895086\">",
"      Patient history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24895116\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Assessment by imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24895270\">",
"      Assessment by acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24895277\">",
"      Extraarticular involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Recommendations for office practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prognostic indicators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NONPHARMACOLOGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24895494\">",
"      Analgesics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Tumor necrosis factor alpha antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Overall efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15027495\">",
"      - Use of TNF antagonists in early and advanced axial spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Predictors of response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15027527\">",
"      - Switching to a second TNF antagonist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15027553\">",
"      - Stopping TNF antagonists when patients have obtained a major clinical response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15027594\">",
"      - Improvement in bone density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - General side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Infliximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Etanercept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Adalimumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Golimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Can TNF antagonists halt progression of AS?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24895511\">",
"      Disease modifying agents (DMARDs)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Sulfasalazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6377225\">",
"      - Other DMARDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Spinal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7790\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7790|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/33/5663\" title=\"diagnostic image 1A\">",
"      Bamboo spine in AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/10/34991\" title=\"diagnostic image 1B\">",
"      Fusion of sacroiliac joints AS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7790|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/22/3439\" title=\"figure 1\">",
"      Cervical flexion deformity AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/39/6768\" title=\"figure 2\">",
"      Low back flexion test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/54/7023\" title=\"figure 3A\">",
"      Flexion hip deformity in AS I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/30/29152\" title=\"figure 3B\">",
"      Flexion hip deformity in AS II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7790|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/57/28571\" title=\"table 1\">",
"      AS clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/19/13629\" title=\"table 2\">",
"      BASDAI on an NRS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10375?source=related_link\">",
"      COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/39/1658?source=related_link\">",
"      Complications of total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=related_link\">",
"      Diagnosis and differential diagnosis of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17782?source=related_link\">",
"      General guidelines for use of anti-tumor necrosis factor alpha agents in ankylosing spondylitis and axial spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=related_link\">",
"      Patient information: Ankylosing spondylitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=related_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41273?source=related_link\">",
"      Psychosocial factors and rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=related_link\">",
"      Spondyloarthropathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=related_link\">",
"      Total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_23_35195="Adverse effects of dapsone";
var content_f34_23_35195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adverse effects of dapsone",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Adverse effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Hemolysis",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Usually a compensated hemolysis but can be severe. Need to monitor with routine complete blood counts.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Agranulocytosis",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"       <td>",
"        Can be severe and life-threatening. Usually occurs in the first few months of treatment.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Methemoglobinemia",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Usually asymptomatic. Symptomatic methemoglobinemia (cardiopulmonary symptoms) should be evaluated and requires alteration of dose or discontinuation of dapsone.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Hypersensitivity syndrome (DRESS)",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Life-threatening. Fever, lymphadenopathy, eosinophilia, flu-like symptoms, hepatitis, morbilliform skin eruption. Immediately discontinue dapsone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral neuropathy",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"       <td>",
"        Usually seen in patients with high daily doses of dapsone and high cumulative doses. Can be motor, sensory, or mixed neuropathy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DRESS: drug rash with eosinophilia and systemic symptoms.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35195=[""].join("\n");
var outline_f34_23_35195=null;
var title_f34_23_35196="Transfusion guidelines for the newborn infant";
var content_f34_23_35196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Transfusion guidelines for the newborn infant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A central hematocrit should be obtained on admission. No further hematocrits should be obtained unless specifically ordered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute red blood cell transfusions should generally only be considered in the setting of acute blood volume loss of &ge;10 percent associated with symptoms of decreased oxygen delivery occurs, or if acute blood volume loss of &gt;20 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In term and preterm infants, a transfusion should be considered if an immediate need for increased oxygen delivery to tissues is suspected based upon the clinical status of the patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volume of transfusion should be 20 mL/kg PRBC unless the Hct is &gt;29 percent. 20 mL/kg volume may be used if significant phlebotomy losses are anticipated in small infants with Hct &gt;29 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For infants receiving erythropoietin, considerations to the above guidelines should be made regarding the rate of decrease in hemoglobin or hematocrit, the infant's reticulocyte count, the postnatal day of age, the need for supplemental oxygen, and the overall stability of the infant.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central measurements of hemoglobin or hematocrit are preferred; alternatively, heelstick measurements may be obtained after warming the heel adequately. An infant meeting the criteria below should not be automatically transfused. Transfusions based upon hemoglobin or hematocrit triggers can be considered for the following clinical setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1) For infants requiring moderate or significant mechanical ventilation, defined as mean air pressure (MAP) &gt;8 cm H2O and FiO2 &gt;0.40 on a conventional ventilator, or MAP &gt;14 and FiO2 &gt;0.40 on high frequency ventilator, and with a hematocrit &le;30 percent (hemoglobin &le;10 g/dL).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2) For infants requiring minimal mechanical ventilation, defined as MAP &le;8 cm H2O and/or FiO2 &le;0.40 on a conventional ventilator, or MAP &lt;14 and/or FiO2 &lt;0.40 on high frequency, and with a hematocrit &le;25 percent (hemoglobin &le;8 g/dL).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        3) For infants on supplemental oxygen who are not requiring mechanical ventilation, transfusions can be considered if the hematocrit is &le;20 percent (hemoglobin &le;7 g/dL) and one or more of the following conditions is present:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - &ge;24 hours of tachycardia (heart rate &gt;180 beats per minute) or tachypnea (RR &gt;60 breaths per minute)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Doubling of the oxygen requirement from the previous 48 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Serum lactate &ge;2.5 mEq/L or an acute metabolic acidosis (pH &lt;7.20)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Weight gain &lt;10 grams/kg/day over the previous 4 days while receiving &ge;120 kcal/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - If the infant will undergo major surgery within 72 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4) For infants without any symptoms, transfusions can be considered if the hematocrit is &le;18 percent (hemoglobin &le;6 g/dL) associated with an absolute reticulocyte count &lt;100,000 cells/microL (&lt;2 percent).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PRBC: packed red blood cell; Hct: hematocrit.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Robin Ohls.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35196=[""].join("\n");
var outline_f34_23_35196=null;
var title_f34_23_35197="Gilliam classification skin LE";
var content_f34_23_35197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gilliam classification of skin lesions associated with LE",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Specific skin disease (cutaneous LE [CLE])",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Acute cutaneous LE [ACLE]",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            1. Localized ACLE (malar rash; butterfly rash)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            2. Generalized ACLE (lupus, maculopaoular rash, SLE rash, photosensitive lupus dermatitis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Subacute cutaneous LE [SCLE]",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            1. Annular SCLE (lupus marginatus, symmetric erythema centrifugum, autoimmune annular erythema, lupus erythematosus gyratus repens)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            2. Papulosquamous SCLE (disseminated DLE, subacute disseminated LE, superficial disseminated LE, psoriasiform LE, pityriasiform LE and maculopapular photosensitive LE)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Chronic cutaneous LE (CCLE)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            1. Classic discoid LE [DLE]",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            a. Localized DLE",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            b. Generalized DLE",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            2. Hypertrophic/verrucous DLE",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            3. Lupus profundus/lupus panniculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            4. Mucosal DLE",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            a. Oral DLE",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            b. Conjunctival DLE",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            5. Lupus tumidus (urticarial plaque of LE)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            6. Chilblains LE (chilblains lupus)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            7. Lichenoid DLE (LE/lichen planus overlap, lupus planus) nonspecific skin disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cutaneous vascular disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            1. Vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            a. Leukocytoclastic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            (1) Palpable purpura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            (2) Urticarial vasculitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            b. Periarteritis nodosa-like cutaneous lesions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            2. Vasculopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            a. Degos' disease-like lesions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            b. Secondary atrophie blanche (livedoid vasculitis, livedo vasculitis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3. Periungual telangiectasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            4. Livedo reticularis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            5. Thrombophlebitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            6. Raynaud's phenomenom",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            7. Erythromelalgia (erythermalgia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Nonscarring alopecia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            1. \"Lupus hair\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            2. Telogen effluvium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            3. Alopecia areata",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other cutaneous manifestations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sclerodactly",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatoid nodules",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Calcinosis cutis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            LE-nonspecific bullous lesions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urticaria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Papulonodular mucinosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cutis laxa/anetoderma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acanthosis nigricans (type B insulin resistance)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythema multiforme",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leg ulcers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lichen planus",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LE: Lupus erythematosus",
"     <br>",
"      Alternative or synonymous terms are listed in parentheses; abbreviations are indicated in brackets.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sontheimer, RD. The lesions of cutaneous lupus erythematosus-a review and personal perspective on nomenclature and classification of cutaneous manifestations of lupus erythematosus. Lupus 1997; 6:84. Copyright &copy;1997 Arnold Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35197=[""].join("\n");
var outline_f34_23_35197=null;
var title_f34_23_35198="Bicycle helmet fit";
var content_f34_23_35198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bicycle helmet fit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 197px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A properly fitting bicycle helmet should rest just above the eyebrows and not slide around on the head. The straps of the helmet should be adjusted to form a \"Y\" just under the ear of the child. The chin strap should be snug enough to pull down on the helmet when the child opens the mouth wide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35198=[""].join("\n");
var outline_f34_23_35198=null;
var title_f34_23_35199="Ultrasound of filarial dance";
var content_f34_23_35199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/ID/56312/US_filarial_dance_video.mp4?title=Ultrasound+of+filarial+dance\" style=\"width:320px;height:272px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of filarial dance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse scan of left testis. In para-testicular position an enlarged lymphatic vessel can be seen (arrow). One or more adult worms are detectable by their typical movements (filaria dance sign). The following m-mode imaging presents the dilated lymphatic vessels, containing moving adult worms, as a section marked by the cursor in the b-mode image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Mand S, Marfo-Debrekyei Y, Dittrich M, et al. Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis. Filaria J 2003; 2:3. Available at:",
"     <a href=\"file://www.filariajournal.com/content/2/1/3\" target=\"_blank\">",
"      file://www.filariajournal.com/content/2/1/3",
"     </a>",
"     . Copyright &copy; 2003 BioMed Central Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_23_35199=[""].join("\n");
var outline_f34_23_35199=null;
